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ABSTRACT 
 
 
Tetratricopeptide (TPR) repeats are a 34-residue helix-turn-helix motif that when 
repeated pack into a superhelical structure.  TPR domains are frequently found mediating 
protein-protein interactions, often through a central groove.  One protein complex bearing 
numerous TPR repeats is the Anaphase Promoting Complex (APC).  The anaphase-
promoting complex (APC) is a multi-subunit complex, which orchestrates mitotic cell 
cycles. APC is an E3 ligase in the ubiquitin cascade, and directs the 26S proteosome 
degradation of cell-cycle regulators. Throughout mitotic progression, proteins that are 
key regulators of the cell cycle are assembled with polyubiquitin chains by APC. 
 
One domain of the human APC is comprised of four related TPR proteins, APC8, 
APC6, APC3, and APC7, with each found in pairs.  Crystal structures of some of these 
indicate that each has an N-terminal dimerization domain and a C-terminal domain that 
APC3 extends away from the dimer interface.  The TPR C-terminal domains are thought 
to play major roles in mediating protein interactions within the APC. 
 
The subunit APC3 plays major roles in regulating APC function.  Within an 
APC3 dimer, each C-terminal domain recruits the Ile-Arg motifs of substrate coreceptors 
Cdh1 (or Cdc20) and APC10.  Cdh1 and APC10 together recruit substrates for 
ubiquitination.  Therefore, it is important to understand the structure of APC3, and how 
APC3 mediates interactions.  To address this problem, I used a novel “hybrid TPR” 
technology, in which some TPRs from a distant relative of APC3 are fused upstream of 
the C-terminal domain from human APC3.  This approach enabled determination of a 3Å 
resolution structure encompassing the sequence of the APC3 C-terminal domain.  
Interestingly, only a fraction of the structure resembles canonical TPR repeats.  
Interpretation of the crystal structure based on published structures of complexes between 
TPR proteins and their partners, and on published electron microscopy structures of 
APC-Cdh1-APC10, reveal that the region containing the Cdh1/APC10 binding site 
adopts 3 canonical TPR repeats.  The remainder of the portion of the structure 
corresponding to human APC3 is folded into an alternative conformation, in which a 
helix from the atypical portion of APC3 buries the Cdh1/APC10-interacting groove 
within the crystal.  Accordingly, unlike wild-type APC3, the hybrid TPR APC3 fails to 
bind Cdh1 and APC10.  Nonetheless, the crystal structure of “hybrid TPR APC3 C-
terminal domain” allows the prediction of potentially important residues for binding to 
Cdh1 and APC10.  Taken together, the data reveal strengths and weaknesses of hybrid 
TPR technology for obtaining structural insights into TPR subunits of multiprotein 
assemblies such as APC. 
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CHAPTER 1. INTRODUCTION 
 
 
APC Regulates Cell Cycle Progression 
 
The anaphase-promoting complex (APC) is a multi-subunit Cullin-RING E3 
ubiquitin ligase that regulates cell cycle progression through mitosis. One of the most 
important functions of APC is to decorate key regulator proteins of the cell cycle with 
polyubiquitinchains conjugated to initiate their proteolysis by the 26S proteasome.  
 
 
Cell cycle brief introduction 
 
The eukaryotic cell cycle is the process during which the cell replicates its 
genomic DNA, and divides the DNA equally between two newly replicated daughter cell 
through mitosis. The precise DNA duplication and cell division are critical to maintain 
normal function during cell reproduction. The cell cycle is divided into a long interphase 
and a relatively short mitotic phase. Interphase is the time that cells prepares themselves 
for the process of cell division. It is further divided into phases of G1 (1st gap phase), S 
(synthetic phase) and G2 (2nd gap phase). The cells grow in the G1 and G2 phases by 
producing proteins and cytoplasmic organelles. In S phase, cells replicate DNA and 
duplicate the genome. The duplicated genome is split during mitosis and separated into 
two identical sets. The division of the entire cell (cytokinesis) followed mitosis, and 
mitosis and cytokinesis together comprise the mitotic phase. Based on the order of 
mitotic progression, mitosis is further divided into prophase, prometaphase, metaphase, 
anaphase, and telophase prior to cytokinesis.  
 
To ensure the appropriate complement of genetic material and equally distributed 
cellular components between daughter cells, cells use “checkpoint” control mechanisms 
to guarantee cell cycle events to occur in a precise order. 
 
 
An overview of ubiquitin cascade 
 
The ubiquitin cascade is an event prior to the major pathway for misfolded or 
unwanted protein degradation. Ubiquitin is a small protein (~8.6kDa) and it is normally 
covalently attached to proteins through its C-terminal glycine residues linked to the lysine 
residues of proteins via an isopeptide bond. This process is known as ubiquitination. 
Following the first ubiquitin, a second ubiquitin molecule is added to the first one by 
linking its last C-terminal glycine residue to a lysine of the first ubiquitin. The repeating 
of this step eventually yields a polyubiquitin chain. Ubiquitin has seven lysine residues 
that may serve as ubiquitination points, the K48-linked and K63-linked polyubiquitin 
chains being best characterized. The K48-linked polyubiquitin chain mediates 
proteasome-dependent degradation while the K63-linked chains are associated with 
cellular signaling (1-3). 
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Three types of enzymes, E1s, E2s and E3s, mediate the ubiquitination cascade. 
They are also known as ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, 
and ubiquitin ligases, respectively.  At the start of the ubiquitination cascade, ATP 
activates ubiquitin by forming a C-terminal acyl adenylated ubiquitin. The cascade 
continues with an E1 catalytic cysteine forming a thioester bond with ubiquitin C-
terminal carboxyl group. Catalyzed by E2, the ubiquitin transfers from E1 to an active E2 
cysteine through a trans-esterification reaction. At the final step, E3 specifically 
recognizes substrates and catalyzes ubiquitin transfer to Nε-amino group of substrate or 
ubiquitin lysines. 
 
In the ubiquitination cascade pathway, E1 can bind with many E2s, which can 
bind with hundreds of E3s in a hierarchical way. Correspondingly, there are two E1s, tens 
of E2s and hundreds of E3s in the human proteome to mediate the ubiquitination 
targeting thousands of substrates. E3 ligases are generally divided into two categories: 
HECT (Homologous to E6-AP Carboxyl Terminus) E3s and RING (Really Interesting 
New Gene) E3s. HECT E3s form a covalent E3-ubiquitin intermediate (via a thioester 
bond with the ubiquitin C-terminus) to mediate ubiquitin transfer (4), whereas RING E3s 
directly transfer ubiquitin from E2 enzymes to substrate without a covalent intermediate. 
The RING domain does not directly participate in the reaction (5). RING E3s represent 
the largest structural class of ligases and APC (Anaphase-Promoting Complex) belongs 
to the RING E3 ligase family (Figure 1-1).   
 
 
The APC directs cell division via substrate destruction 
 
The APC orchestrates mitosis and G1 by sequentially promoting degradation of 
key cell-cycle regulators. APC is found in its active form at the onset of mitosis (Figure 
1-2). Some well-studied APC substrates, notably mitotic Cyclins, Securin, Geminin, 
AuroraA and Hsl1, could be divided as early substrates and late substrates based on their 
degradation timing. (i) Cyclin A and Nek2A are early substrates and are recognized by 
APC at prometaphase (6, 7). Cyclin A forms complexes with Cdk1 and Cdk2 that support 
S-phase and G2-phase progression. Nek2A is a mammalian kinase required to ensure the 
correct formation of mitotic spindles at mitosis onset. Decreasing the cellular 
concentrations of Cyclin A and Nek2A allows mitosis to enter into metaphase. (ii) To 
promote cell cycle transition from metaphase to anaphase (when sister chromatids 
separate), APC assembles polyubiquitin chains to degrade Securin. The degradation of 
Securin releases Separase, a protease, which advances sister chromatid separation by 
cleaving Cohesin (8, 9). (iii) Another substrate that is degraded rapidly during metaphase-
anaphase transition is Geminin. Geminin inhibits DNA replication during S, G2, and M 
phases by preventing the incorporation of the MCM complex (mini-chromosome 
maintenance complex). Destruction of Geminin permits replication in the succeeding cell 
cycle (10). (iv) During late mitosis, APC also targets Cyclin B (and other mitotic Cyclins) 
for degradation, which then deactivates Cdk1. The decreased activity of Cdk1 plays a 
critical role in mitotic spindle disassembly and chromosome decondensation, which in 
turn promotes cell exiting from mitosis and entry into cytokinesis (11);  (v) Aurora A is 
another late substrate which is quickly degraded after mitosis. Aurora A is essential for   
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Figure 1-1. APC functions as an E3 ligase in ubiquitination cascade. 
 
A ubiquitin (yellow) is initially activated by an E1 (activating enzyme, cyan) and is 
driven by hydrolysis of an ATP molecule. The ubiquitin then forms a thioester linkage 
with the catalytic cysteine of the E1. Next, the E1 recruits an E2 (magenta) and transfers 
the ubiquitin to the E2 catalytic cysteine. Finally, with the aid of the E3, APC (light 
orange), the ubiquitin is transferred to a lysine on the target substrate.  
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Figure 1-2. The order of APC substrate destruction. 
 
The activity of APC is first inhibited by a protein complex called the spindle assembly 
checkpoint (SAC), which interacts with Cdc20 and thereby blocks substrate recruitment 
by APC. Cyclin A and the kinase Nek2A are two of prometaphase targets and they are 
ubiquitinated by APC without being recognized by Cdc20. SAC is inactivated when all 
the sister-chromatid pairs are attached to the spindle, allowing an activated active APC to 
target metaphase substrates, like Securin and Cyclin B. Cyclin destruction leads to cyclin-
dependent kinase (Cdk) inactivation, which results in the dephosphorylation and 
activation of the second APC activator, Cdh1. APCCdh1 triggers the destruction of various 
targets at late mitosis (from anaphase to telophase), like Geminin, Cdc20 and Aurora A. 
These substrates are degraded at different times, presumably providing mechanisms that 
order late mitotic events. Key mitotic events are labeled out in text boxes along with the 
cell-cycle time course.  
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proper centrosome separation once the mitotic spindle is formed (12). (vi) Hsl1 is a 
substrate of the budding yeast APC (13), which accumulates after G1 phase as cells begin 
to bud but disappears in late mitosis. Hsl1 promotes the degradation of yeast cytoskeletal 
proteins and allows cells to proceed to mitosis (13). 
 
The APC adopts a similar two-step mechanism to other ubiquitin ligases to 
assemble a polyubiquitin chain.  The E2 UbcH10 functions as a “priming” E2, whereby 
the APC specifically mono-ubiquitinates substrates (14). The second E2 Ube2S elongates 
the ubiquitin chain.  The APC triggers substrate degradation by assembling K11-linked 
ubiquitin chains, and the specificity of this chain formation depends on a surface of 
ubiquitin (15). APC is the largest of the RING E3 family, which are characterized by 
direct ubiquitin transfer from E2 to substrates without forming a covalent intermediate 
(16, 17). APC positions both a substrate and a ubiquitin conjugated UbcH10 in close 
proximity to facilitate ubiquitin transfer to substrate lysines. 
 
 
APC Architecture and Subunit Organization 
 
 
APC subunit organization 
 
The human APC consists of 14 subunits and has a molecular weight around 
1.2MDa (Table 1-1). Based on biochemical and genetic data, the complex is considered 
to have two large domains, called the “arc lamp” and the “platform”, which together 
enclose a central cavity (Figure 1-3). The arc lamp is comprised of tetratricopeptide 
repeat (TPR) proteins APC7, APC3, APC6, and APC8 with small subunits APC16, 
Cdc26 and APC13. The arc lamp is therefore also called TPR arm. The platform consists 
of APC1, APC4, APC5, and APC15 (18). The catalytic core of APC is composed of 
subunits APC2 and APC11, which are analogous to the Cullin and Rbx1 subunits of 
Cullin-RING ligases in the SCF superfamily (19). The Cullin domain of APC2 interacts 
with the RING-finger APC11, which potentially mediates interactions with the ubiquitin 
conjugated E2s (UbcH10 and Ube2S). APC2 and APC11 are neighbored by APC1 inside 
the complex, whereas TPR subunits co-localize to a more distal region to APC1. 
 
With respect to human APC, APC7 is the most peripheral TPR subunit of the “arc 
lamp”, and APC8 is the most internal subunit. APC6 stacks between APC3 and APC8, 
and APC3 stacks between APC7 and APC6. Yeast APC lacks the APC7 subunit, and 
therefore yeast APC3 (Cdc27) is the most peripheral TPR protein. Each TPR subunit 
forms a homo-dimer through their N-terminal domains, and four homo-dimers spirally 
stack together and constitute a TPR arm (20). The TPR arm has the flexibility to support 
APC switching overall conformation between open and closed status (21). 
 
The small subunit APC16 was recently discovered and characterized (22) to be 
important for maintaining APC activity towards mitotic substrates. APC16 associates 
with both APC3 and APC7, and it may function to stabilize interactions between them. 
Another small subunit, APC13, interacts with APC8 and is reported to have a function of
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Table 1-1. The APC core and regulatory subunits.  
 
H. 
sapiens 
S. 
cerevesiae 
S. 
pombe 
Molecular 
mass 
(kDa) 
Stoichiometry Structure motif Function 
APC1 APC1 Cut4 216.5 1 PC repeats Scaffolding subunit 
APC2 APC2 APC2 93.8 1 Cullin homology Catalytic subunit 
APC3 Cdc27 Nuc2 92.6 2 TPR Scaffolding subunit, recruit 
substrate co-receptors 
APC4 APC4 Lid1 92.04 1 β-propeller, extended 
TPR 
Scaffolding subunit 
APC5 APC5 APC5 85.1 1 Extended TPR Scaffolding subunit 
APC6 Cdc16 Cut9 71.7 2 TPR Scaffolding subunit 
APC7 — — 63.2 2 TPR Scaffolding subunit 
APC8 Cdc23 Cut23 68.3 2 TPR Scaffolding subunit 
APC10 Doc1 APC10 21.2 1 β-barrel, IR tail 
peptide 
Substrate co-receptor 
APC11 APC11 APC11 9.84 1 RING-H2 finger Catalytic subunit 
APC13 Swm1 APC13 8.5 1 A few α-helix Stabilize APC8 
APC15 — APC15 14.28 1 A few α-helix Unknown 
APC16 — — 11.67 1 C-terminal long α-
helix 
Stabilize APC7 and APC3 
Cdc26 Cdc26 Hcn1 9.78 2 Unstructured N-
terminal domain, C-
terminal α-helix 
Stabilize APC6 
Cdh1 Cdh1  55.18 1 C-box, WD40 repeat, 
IR tail peptide 
Activator, substrate co-
receptor 
Cdc20 Cdc20  54.72 1 C-box, WD40 repeat, 
IR tail peptide 
Activator, substrate co-
receptor 
 
Molecular mass corresponds to H. sapiens subunits. 
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Figure 1-3. The schematic of the APC subunit topology and the APC architecture. 
 
(a) Schematic representation of human APC showing approximate subunit topology 
based on biochemical and genetic data cited in the text.  
(b) 3D model of human APC. The ‘arc lamp’ and the ‘platform’ domains enclose a 
catalytic cavity. Each subunit is assigned to its corresponding density. The EM map, 
APCCdh1-Emi1 is reprinted from the open source EM databank (EMD 2354) (23, 24). 
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stabilizing association of APC3 and APC6 (25). Cdc26 was proven to be essential for 
proper folding of APC6 (26, 27). APC6 could not be expressed in vitro without Cdc26. In 
the budding yeast, the deletion of Cdc26 resulted in reduced levels of APC6 and APC3 
incorporation into the APC (28). 
 
The largest subunit in the platform of APC is APC1, which has a molecular 
weight more than 200kDa. APC1 C-terminal domain has nine pentatricopeptide repeats 
(PPR), which fold into the helix-turn-helix structure similar to TPR motifs. APC4 
associates with APC5 (29) and subunits APC1, APC4, APC5 interdependently associate 
with each other to form the platform. APC8 connects the TPR arm with the platform. 
 
 
APC recruits co-activators through TPR subunits 
 
Without the co-activators Cdh1 and Cdc20, APC is an inactive E3 ubiquitin 
ligase. Cdh1 and Cdc20 are not the constitutive subunits of APC and they are recruited to 
the complex alternatively during cell cycle phases. By switching between Cdh1 and 
Cdc20, APC specifically targets various cell-cycle regulators during cycle procession. 
 
 TPR subunits APC3 and APC8 contribute to the recruitment of Cdh1 and Cdc20. 
TPR structure motif is a protein-protein interaction module that consists of two 
antiparallel α-helices. Most TPR proteins are characterized by continuous α-helices as 
their secondary structures (30). Both APC3 and APC8 are predicted to have 14 TPR 
motifs and the N-terminal 6 TPR motifs mediates homo-dimerization.  
 
APC3 is required for the Cdc20 and Cdh1 association with APC. Both yeast and 
human APC EM structures reveal that Cdh1 localizes adjacently to the C-terminal 
domain of a molecule within the APC3 homo-dimer (31, 32). Cdh1 could be specifically 
cross-linked to APC3 through multiple crosslinking compounds (33).  In the APC3-
deleted yeast APC, Cdh1 and Cdc20 binding to the complex are dramatically decreased 
compared to the wild type APC (18, 33). These APCs lost the ability to assemble long 
ubiquitin chains onto substrates (the ubiquitin number of most chains is less than three), 
which contributes to the mutated complex having a 100-fold lower activity than wild type 
APC (33, 34). 
 
APC3 C-terminal TPR domains were predicted to recruit co-activators, Cdh1 and 
Cdc20 through their C-terminal Ile-Arg (IR) tail motif (35). The double mutation of two 
conserved residues (N548A and L579A) in yeast APC3 raised the Cdh1 dissociation rate 
from APC without affecting other subunit incorporation.  The APC3 mutant 
(N548A/L579A) reduces the APC ubiquitination activity more than 5-fold once it is 
incorporated into APC (34). The conserved residues N548 and L579 sit on the α-helices 
of TPR8 and 9 of yeast APC3, and therefore TPR8 and 9 are believed to form a binding 
groove responsible for co-activator recruitment.  
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Co-activators interact with the APC through multiple interactions 
 
Cdh1 and Cdc20 are recruited to APC3 through its C-terminal Ile-Arg (IR) tail 
motif. The last two Isoleucine and Arginine residues of Cdh1, Cdc20 and APC10 are 
highly conserved across species (Figure 1-4). APC10 is also found to associate with 
APC3 through its C-terminal IR motif (34, 36). Multiple research groups have found that 
the IR-tail deleted/mutated Cdh1 or Cdc20 have APC-binding defects and contribute to 
APC-activation defects (18, 34, 37). The Arginine to Lysine mutation of the IR-tail 
disrupted the interaction between Cdh1 and APC (38). IR-tail peptides of Cdc20 and 
Cdh1 could bind to APC3 and the peptides inhibit in vitro APC ubiquitination by 
competing with co-activators recruitment to APC (37). The IR-tail peptide of Cdh1 is 
essential for budding yeast viability whereas C-terminal IR-tail peptide of Cdc20 is not 
(18, 33). This may reflect differences in affinities of multiple Cdh1 and Cdc20 binding 
sites on APC, although future studies will be required to know how much each binding 
site contributes. 
 
Cdh1 and Cdc20 also have an eight-residue C-box motif near the N-terminus. The 
C-box enhances the ubiquitination activity of APC though the mechanism is not well 
understood. The C-box containing Cdc20 fragment (N-terminal fragment) enabled the 
ubiquitination of Nek2A to be mediated by the substrate interaction domain, WD40 
domain (a domain comprised of tandem copies of WD40 repeat) (39). The C-box deleted 
Cdh1 caused a large reduction of APC ubiquitination activity. The co-activator C-box 
might promote a change in APC conformation that is independent of the activators’ other 
domains.   
 
A xenopus Cdc20 C-box containing protein fragment was discovered to interact 
with APC through subunit APC3, and the affinity is weaker than the IR motif-APC3 
interaction (40).  Multiple residues of Cdh1 C-box, WD40 domain and IR-tail could be 
cross-linked to APC3, and the residues of the IR-tail demonstrated much stronger cross-
linking interaction than others. However, all the cross-linked interactions disappeared 
once the C-terminal IR peptide is deleted (33). The IR-tail deletion increases Cdh1 partial 
dissociation from APC, and double deletion of C-box and IR motif further increases 
Cdh1 dissociation (34, 37). Cdh1 and Cdc20 seem to have multiple sites mediating low-
affinity interaction with APC and their IR motifs are responsible for anchoring the co-
activators into the correct binding groove of APC3.   
 
The mutation of yeast APC8 conserved residue (N405A) also affected Cdh1 
recruitment. APC3 (N548A and L579A), APC8 (N405A) double-mutant APC caused cell 
cycle arrest in metaphase with high levels of Cyclins (34). This APC8 mutant also 
demonstrates a higher Cdh1 dissociation rate. The mutation of Cdh1 C-box greatly 
reduced the activity of APC8 mutant incorporated APC. Therefore, the residue Asn405 
(N405) in APC8 is likely to interact with a third, unknown site on Cdh1.  
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Figure 1-4. Sequence alignment of C-terminal APC10, Cdh1 and Cdc20.   
 
Sequence alignment of the C-terminal Cdh1, Cdc20 and APC10 from human (Hs), 
Mouse (Mm), Drosophila melanogaster (Dm), Arabidopsis thaliana (At), Dictyostelium 
discoideum (Dd), Saccharomyces cerevisiae (Sc), Schizosaccharomyces pombe (Sp). The 
last two residues, Isoleucine and Arginine, are highly conserved across different species.  
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Substrate recruitment to APC through the co-activators and APC10 
 
APC has weak interaction with substrates without its co-activators (38, 41). The 
role of the co-activators is to act as a substrate recognition subunit and recruit substrates, 
which is analogous to the F-box protein receptors of the SCF. Substrates of the APC 
contain conserved APC-targeting sequence elements: the KEN and destruction box (D-
box). D-box and KEN box motifs are characterized with peptide sequences 
RxxLxxI/VxN and KENxxxN/D, respectively. 
 
Cdh1 and Cdc20 each contain a WD40 domain which folds into a seven-blade β-
propeller structure. This domain functions as a destruction box (D-box) receptor to bind 
substrates. The fact that WD40 domains of Cdc20 and Cdh1 could be cross-linked to 
substrates in a D-box-dependent manner confirms a role for co-activators in recruiting of 
substrates to the APC core (33, 42). Moreover, residue mutations of the evolutionarily 
conserved surface of WD40 domains abolish crosslinking interactions with substrates 
(33). 
 
Human and yeast APC EM structures explicitly revealed the interaction between 
Cdh1 and substrates.  The apo APC EM map demonstrated that Cdh1 and APC10 have 
separated density in close proximity. APC10 is an APC subunit localizing at the opposite 
side of the catalytic center from Cdh1. When the substrate Hsl1 is bound, the β-propeller 
domain (WD40 domain) of Cdh1 shifted approximately 7Å towards APC10. The 
repositioning of Cdh1 created a well-defined density to bridge the gap between them 
(Figure 1-5).  The KEN box of Hsl1 alone also promoted repositioning of Cdh1 towards 
APC10, but there wasn’t connecting density between KEN box and APC10. It seemed 
that only the D-box of substrates contributed to the physical connection between Cdh1 
and APC10. Cdh1, Hsl1 and APC10 together form a three-layer structure (31, 32).  
 
Arginine and Leucine residues appear as two invariant residues inside the D-box 
motif (RxxLxxI/VxN), and the C-terminal Asparagine residue is less conserved. 
Mutations of Arginine and/or Leucine eliminate the recruitment of this motif to the co-
receptors. The D-box of the substrates directly interacts with the WD40 propeller 
structure of Cdh1, and this interaction is essential for ubiquitination processivity (33). 
The mutated D-box and KEN box also abolished substrate recognition and recruitment to 
the APC (34, 38, 41). 
 
The use of two distinct motifs for substrate recognition introduces a greater 
degree of substrate specificity. APCCdh1 is also able to ubiquitinate substrates containing 
only a KEN box motif, such as Cdc20 and Sororin. Contrastingly, APCCdc20 recognition 
of substrates requires the D-box motif. The conformation of the KEN and D-box are 
different when they are bound to Cdc20. It has recently been reported that the KEN box 
folds into an underwound helix, whereas the D-box is potentially an extended structure 
(Figure 1-5) (43, 44). The optimal spatial arrangement of KEN and D-box is not well 
understood. But the Cdh1 inhibitor Acm1 and Mes1 have the spacing of 18 and 24 
residues, respectively, between the KEN and D-box motifs, which optimize their affinity 
to the co-activators (45).   
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Figure 1-5. Detail and schematic demonstration of Cdh1 and APC10 as APC 
substrate co-receptors.  
 
Left: Schematic diagram of the substrate-recognition module responsible for the D-box 
and KEN box binding, and Cdh1 and APC10 recruitment to the APC3 homo-dimer. D-
box is represented as a box in the interface between Cdh1 and APC10. Right: Details of 
the Cdh1 and APC10 functioning as co-receptors to the D-box. Hsl1’s D-box is recruited 
to Cdh1 between blade 1 and 7, while KEN box is recruited to the surface at the center of 
the bottom side of the WD40 domain. APC10 faces toward D-box with its substrate-
binding pocket. APCCdh1-Emi1 EM map (EMD 2354) (23) is used for the structural 
demonstration. 
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It is also not well understood whether there is an optimal distance between a 
target Lysine (the ubiquitin acceptor residue) and the KEN or D-box motifs. Randall 
King’s group reported that 15 residues between the D-box and the target Lysine is 
sufficient to support the degradation of the D-box fused proteinA (46). A C-terminal 
Lysine immediately following the D-box peptides (of CyclinB1 and Securin) functioned 
as a ubiquitin acceptor (33). Lysines preceeding the D-box in Cyclin B from S. pombe 
also accepted ubiquitins and mutating them made a D-box containing peptide non-
ubiquitinable (47).  
 
 
The contribution of APC10 to APC processivity 
 
APC10 is a constituent subunit of the APC and binds to APC3 through its C-
terminal IR motif. APC10 acts as another co-receptor for the APC substrates (31, 32, 48, 
49). APC10 adopts a β-barrel (jellyroll) fold with a binding pocket structure, both 
structurally similar to galactose oxidase (36, 50). APC10 is necessary for optimal 
Cdh1/Cdc20-dependent substrate recognition, through which APC10 contributes to 
substrate processivity (38). The mutation of conserved residues in the APC10 binding 
pocket affected substrate processivity, and the deletion of the entire subunit impaired 
polyubiquitin assembly in a D-box-dependent manner (48, 49). The docking of the 
APC10 crystallographic model into APC EM maps displays that a conserved loop of 
APC10 faces toward the substrate D-box (Figure 1-5). However, the interaction affinity 
between APC10 and substrates is pretty low. Da Fonseca and Kong et al demonstrated 
the weak interaction of APC10 to the substrate D-box through HSQC-type NMR 
experiments, whereas the substrate KEN box didn’t appear to interact (32).  
 
There is a bipartite model to interpret the contribution to the substrate recruitment 
by APC10. In this model, the D-box of substrates may form a divalent connection to 
bridge a co-activator and APC10. APC10 potentially stabilizes the association of co-
activator-substrate to APC through this bipartite interaction (divalent bridge), which 
probably results in a higher ubiquitination processivity. The mutant APC lacking the 
APC10 subunit displays a 50-fold reduction in the Cyclin recruitment and the Cyclin B 
peptides interacted more efficiently with Cdc20 when it is bound to the holoAPC (33, 
49). Hsl1 enhanced the Cdh1 association to the APC in vivo and Cyclin B enhanced this 
association in vitro (34). Individually, both the co-activators and APC have low affinity 
and specificity for substrates (41). APC10 probably stabilizes Cdh1 binding to APC 
through the D-box of substrates. 
 
APC10 promotes APC processivity in an E2 independent manner. APCΔAPC10 
produces less ubiquitinated Cyclins due to the poorly bounded substrates to the complex 
(49). But the interactions between the APC and E2s are not compromised in the absence 
of APC10, and E2s show similar effects to promote the activity of both wild type APC 
and the APCΔAPC10.  
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TAME is an IR-tail mimic APC inhibitor 
 
TAME (tosyl-L-arginine methyl ester), is a small molecule, which structurally 
resembles the IR motifs of the APC co-activators and APC10. The benzyl ring of the 
tosyl group mimics the hydrophobic interaction contributed from Isoleucine of the IR 
motifs.  TAME is reported to inhibit the APC activation by preventing Cdc20 and Cdh1 
binding. In an assay TAME almost completely disrupted Cdc20 association to the APC 
and prevented polyubiquitin chains from being assembled onto Cyclin B (51).  TAME 
specifically antagonizes the IR motif-dependent interactions without inhibiting other 
interactions between the co-activators and APC. The compound disrupted the IR-tail 
peptides which were cross-linked to APC but didn’t affect the recruitment of the IR motif 
deleted co-activators or the C-box only fragments of the co-activators (40). Similar to the 
IR-tail peptides reduction of the APC Kcat, TAME slows the Kcat of the APCCdc20 by a 
~55%, while the amount of the Cdc20 associated to the APC is not reduced (51). 
Whether or not TAME affects APC10 is not well understood. 
 
TAME induces Cdc20 dissociation from the APC by promoting Cdc20 
ubiquitination. The ubiquitination of Cdc20 is upstream of the C-box, reducing its 
binding affinity for the APC. Cyclin B promotes the Cdc20 binding to the APC and 
suppressed Cdc20 ubiquitination (40, 51). A cell-permeable prodrug (proTAME) is 
capable of inhibiting APC-Cdh1 activation during S phase, and induces mitotic arrest in a 
SAC dependent manner. HeLa cells treated with 12 μM proTAME were arrested in 
metaphase without mitotic spindle disruption. ProTAME also greatly increased mitotic 
duration in asynchronous hTERT-RPE1 cells (51).  
 
 
Crystallography study of APC subunits 
 
It is still mysterious why the APC is such a large complex, comprised of a large 
number of subunits. Structural studies of the APC subunits have yielded crystallographic 
structures of numerous TPR subunits and substrate co-receptors: APC6-Cdc26 complex 
from human and yeast (PDB code: 3HYM, 2XPI), APC3 N-terminal dimer domain from 
E. cuniculi (PDB code: 3KAE), and APC8 N-terminal domain from S. pombe. The co-
receptor APC10 structures were determined from both the yeast and human proteins, but 
the C-terminal peptides and IR motifs are missing in these atomic models (Figure 1-6). 
The WD40 domain of yeast Cdh1 was co-determined with Cdh1 inhibitor Acm1 (PDB 
code: 4BH6). Cdc20 of both human and yeast were determined together with the MCC 
complex subunits (PDB code: 4AEZ, 4GGD). 
 
From these studies, APC3, APC6 and APC8 were found to form homo-dimers, 
with an interlocking dimer interface mediated by the self-association of their N-terminal 
TPR motifs. The overall structure of APC6 displays a TPR superhelix created by seven 
successive TPR motifs. The superhelix features each APC6 subunit/monomer in a rod-
like structure of a continuous 14 TPR motifs (27). The N-terminal 13 residues of Cdc26 
extend into the inner concave groove of the APC6 superhelix (from the C-terminal 
APC6) and stabilize the superhelix conformation through intimate interactions   
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Figure 1-6. Crystal structures of APC10, Cdh1, and Cdc20. 
 
Cartoon views of the overall structures of all the available atomic models from APC10, 
Cdh1 and Cdc20. All the atomic models have C-terminal around 20 residues absent. 
Human and yeast APC10 both adopt β-barrel structure except yeast APC10 has a longer 
N-terminal α-helix. The models of Cdh1 and Cdc20 miss the N-terminal ~160 residues, 
but Mad2 interaction domain of yeast Cdc20 is visible in structure.  
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(Figure 1-7). The rest of Cdc26 forms an α-helix that packs against the APC6 C-terminal 
TPR α-helix (26, 27). 
 
The C-terminal 9 TPR motifs of E. cuniculi APC3 are absent from its crystallized 
N-terminal dimer. The C-terminal APC3 was predicted to form a continuous TPR 
superhelix like APC6. Among all of the C-terminal TPRs, TPR8 and TPR9 are predicted 
to be the motifs recruiting the co-activators and APC10 through their C-terminal IR 
peptides. Matyskiela et al predicted the conserved Asparagine of TPR8 and Leucine of 
TPR9 both engaged in the interactions with the Cdh1 IR motif (34). 
 
The structure of Cdh1-Acm1 demonstrates the D-box of the substrates and 
inhibitors binding to an APC co-activator. The D-box of Acm1 binds to an inter-blade 
groove on Cdh1 (between blade 1 and 7) and the KEN box binds to a conserved surface 
at the center of the topside of WD40 domain. The KEN box recognition sites on Cdh1 are 
likely to be universal through all species. Acm1 uses a motif A and an α-helix, to 
specifically target Cdh1 but not Cdc20. The A motif aligned parallel with β–sheet blade 3 
and interacts with another inter-blade channel (between blade 3 and 4), which is less well 
conserved than the D-box and KEN box interaction regions. Acm1-Cdh1 forms a 
heterodimer to inhibit the APC activation.  
 
The structure of Cdc20 is determined within the MCC complex (mitotic 
checkpoint complex, PDB code: 4AEZ, 4GGD). Human Cdc20 is comprised of a WD40 
domain forming a β propeller with a preformed KEN box binding site at its top surface. 
Both human and yeast Cdc20 use a deep hydrophobic pocket at the surface of blades 1 
and 7, to interact with the D-box Leucine residue (RxxLxxI/VxN) (43, 44). The pocket is 
created from the conserved non-polar residues on the surface. The mutants of D-box 
interacting residues diminish the ubiquitination ability whereas the mutants of KEN box-
binding site lack such deficiency. Blocking the Leucine-binding pocket with small 
molecules may be a potential mechanism to inhibit APCco-activator activity (43, 44).  
 
The affinity of Cdc20 for the substrate D-boxes is weaker than Cdh1. Unlike 
Cdh1, Cdc20 residues could not crosslink to substrates the way Cdh1 could, although 
they localize at the equivalent sites of the WD40 domain (33, 43). KEN box contacting 
sites are also dispensable for APCCdc20 ubiquitination of Securin, where the same sites on 
Cdh1 are essential for APCCdh1 activity (43).  
 
An alternative structural approach to study APC assembly is through Electron 
Microscopy. Yeast APC EM structures were determined using cryo-electron microscopy, 
whereas the human and Xenopus structures were determined by the approaches of both 
cryo- and cryo-negative stain electron microscopy. The effective resolution is of the order 
of 10-20Å.  
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Figure 1-7. APC6 adopts a superhelix structure.  
 
Surface density of S. pombe and human APC6 structure (left) demonstrate that APC6 
continuous TPR motifs form the superhelix tertiary structures. Two structures were 
superimposed onto each other with an r.m.s.d of 1.77Å (right), and N-terminal Cdc26 
stabilizes APC6 tertiary structure through interactions with the superhelix inner groove. 
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APC Activity Regulation 
 
There are multiple complexes involved in cell-cycle control system to coordinate 
cell cycle progression.  The Emi1 (early mitotic inhibitor 1) protein and mitotic 
checkpoint complex (MCC) inhibit the APC activity by mimicking substrate recognition 
motifs; the D-box and/or KEN box. 
 
 
Emi1 inhibition 
 
Emi1 is an inhibitor of the APC and it was first discovered due to its role in 
preventing premature APC activation in early mitosis (52). The APC inhibition by Emi1 
is accomplished through a combination of structure motifs:  a D-box, a conserved zinc-
binding region (ZBR), a linker linking D-box to ZBR and a highly conserved C-terminal 
LRRL tail (Leu-Arg-Arg-Leu) (53). The D-box of Emi1 allows the protein to mimic the 
substrates interaction with the APC and Emi1 is recruited between Cdh1 and APC10 
(23). Comparing with an isolated D-box peptide from the yeast APC substrate Hsl1, the 
isolated Emi1 D-box is relatively weak, although Emi1 competes with the D-box-
dependent substrates to be recruited to the APC (23, 54).  
 
The ZBR of Emi1 provides an APC E3 ligase antagonizing activity (52, 54). 
Interestingly, the mutation of the Emi1 ZBR converts Emi1 to a D-box-dependent APC 
substrate (54). The linker between the D-box and ZBR contributes to inhibition with its 
specific side chains. The Emi1 C-terminal tail is a specific inhibitor to the Ube2S-
dependent ubiquitin-chain formation, and ZBR and C-terminal tail synergize to block 
chain elongation. Much of the Emi1 is predicted to be intrinsically disordered, and this 
disorder has implications for an ability to span over a broad distance of the APC catalytic 
center, although this inhibitor has a relatively small size. The Emi1 D-box, linker, ZBR 
and tail synergistically block both the substrate binding to the APC and ubiquitin chain 
elongation by the APC and Ube2S (23). 
 
 
MCC inhibition 
 
The MCC (Mitotic Checkpoint Complex) is a multi-subunit protein complex that 
is activated by the spindle assembly checkpoint (SAC). The MCC includes the co-
activator Cdc20, which assembles with the other MCC proteins and loses its APC 
activation function.The blocked Cdc20 leads to an inhibited degradation of Securin and 
Cyclin B (substrates of APCCdc20) until late mitosis. This regulatory network of the APC 
activity is contributed from three complexes to ensure that chromatids are attached to 
mitotic spindles and well aligned before onset of the anaphase. However, Nek2A and 
Cyclin A still escape MCC-mediated inhibition (55), being targeted instead at 
prometaphase for ubiquitin-mediated proteolysis. 
  
A couple of EM studies have demonstrated that the MCC localizes to the front 
end of the platform domain (21), and Cdc20 is partially overlapped with MCC. MCC sits 
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in the lower region of the APC cavity. Mad2 contacts the TPR subunits APC8 and APC5, 
whereas Mad3 interacts with APC1 (44). Checkpoint inhibition of APCCdc20 requires the 
binding of a Mad3 (also called BubR1) KEN box to Cdc20. Due to this mechanism, Cdh1 
is required for the exit of mitosis. 
 
The MCC can be assembled in vitro from recombinant Mad2, Mad3 (BubR1), and 
Cdc20 proteins in the absence of kinetochores. Mad2 and Mad3 (BubR1) bind directly to 
Cdc20 and together they inhibit the APCCdc20 activity towards ubiquitinating Securin and 
Cyclin B. The conserved N-terminus of BubR1 that is essential for MCC assembly 
incorporates a KEN box, and the BubR1 N-terminus adopts a helix–loop–helix (HLH) 
structural motif. The HLH motif simultaneously binds Mad2 and Cdc20, orienting the 
KEN box towards its binding residues on the receptor Cdc20 (44). Binding of the N-
terminal Mad3 to Cdc20 is KEN box-dependent (43), and the same KEN box also 
promotes Mad3-dependent APC-mediated Cdc20 degradation (56), which suggests that 
Mad3 plays a role in positioning Cdc20 for ubiquitination mediated by the APC catalytic 
subunits (44). The EM structures of the APC-MCC complex demonstrate that the D-box 
receptor residues are directed towards, but not in contact with, the substrate co-receptor 
APC10 (21, 44). Comparing with the Cdh1 position on APCCdh1, Cdc20 is displaced 
downwards towards APC5, and it is lower than Cdh1. This lower position may facilitate 
Cdc20 ubiquitination. Furthermore, the lower position of Cdc20 prevents its D-box-
binding site from generating a bipartite D-box co-receptor with APC10 (44).   
 
 
Substrate specificity controlled through co-activators 
 
The APC-mediated coordination of cell-cycle progression is achieved through the 
temporal regulation of APC activity. Cdc20 activates the APC during early mitosis when 
Cdh1 is inhibited by its N-terminal phosphorylation. The N-terminus of Cdc20 alone, 
without the substrate-binding WD40 domain, is able to activate the APC catalytic 
activity. The APCCdc20 reduces mitotic Cdk activity through the degradation of Cyclins 
which are required for Cdk activity, which in turn stimulates the APCCdh1 activity. This 
then leads to the APCCdh1 ubiquitinating Cdc20 and deactivating the APCCdc20. The 
APCCdc20 and APCCdh1 have different substrate specificities. Dynamic changes in the co-
activator positions relative to core APC subunits may provide the combinations of 
substrate-recognition interfaces. 
 
In addition to the D-box and KEN box binding sites, the APCco-activators utilize 
additional recognition sites to bind substrates and regulatory proteins. The C-terminal 
Met-Arg (MR) residues of Nek2A are structurally related to the IR-tails of the co-
activators and APC10, and are directly recruited to APC in a MR-dependent manner (55). 
The Nek2A MR tail may engage the IR motif binding sites of APC3. Cyclin A is 
recruited to the APC through its binding partner Cks1(56) that recognizes the 
phosphorylated APC3 of the TPR arm (57).   
 
The N-terminal Cdc20 facilitates Nek2A destruction in a C-box-dependent 
manner in Cdc20-depleted cells (39). Cdc20 is required for the degradation of Nek2A and 
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Cyclin A, but it does not mediate their binding to the APC at prometaphase. This renders 
their degradation insensitive to the mitotic checkpoint complex (39, 55, 57).  The 
ubiquitination of Cdc20 is not required to release it from the checkpoint complex, but to 
degrade it to maintain mitotic arrest (56). 
 
 
APC activity regulation via UbcH10 auto-ubiquitination 
 
Coupling of APC activity to E2s provides another mechanism of regulation. Once 
a substrate is bound to APC, several different ubiquitin-conjugating enzymes will 
catalyze the ubiquitin chain assembly. UbcH10 or UbcH5 (Ubc4 in yeast) catalyzes 
mono-ubiquitination onto the substrate lysines, followed by Ube2S (Ubc1 in yeast) 
assembling a Lys11-linked poly ubiquitin chain onto the pre-attached ubiquitins (58-60). 
The Ubc1 of S. cerevisiae assembles a Lys48-linked poly ubiquitin chain onto the yeast 
APC substrates (61). 
  
The UbcH10 N-terminus sets a threshold for APC activation by limiting the APC 
activity for substrate selection and checkpoint control. Mutations of the highly conserved 
UbcH10 N-terminus increase substrate ubiquitination and the number of targeted lysines 
on substrates, allow ubiquitination of the APC substrates without a D-box, increase 
resistance to the APC inhibitors Emi1 and MCC in vitro and bypass the SAC (spindle 
assembly checkpoint) in vivo (14). These regulations guarantee that ubiquitin transfer by 
the E2 won’t overcome the unmet criteria, in order to avoid the inappropriate 
ubiquitination and unwanted substrate destruction. 
 
The UbcH10 is a target of APCCdh1-mediated ubiquitination and degradation of 
UbcH10 inactivates the APC. Cyclin A inhibits the auto-ubiquitination of UbcH10, but 
not its E2 function. Therefore, the ubiquitination of UbcH10 will occur after high-affinity 
substrates, such as Cyclins, are degraded. Because of this mechanism, the APC activity is 
maintained as long as G1 substrates present (62). During G1 phase, the APC 
autonomously switches to a state permissive for Cyclin A accumulation. UbcH10 
accumulates at a similar time to Cyclin A in late G1 phase and is degraded in mitosis 
(63). The APC is inactivated after mitosis exit. 
 
Auto-ubiquitination of UbcH10 is regulated by a conserved N-terminal extension 
of UbcH10, which is unique among E2 enzymes. The deletion of the N-terminal UbcH10 
impairs the formation of ubiquitin chains by APCCdh1 but simultaneously allows some 
UbcH10 ubiquitination by APCCdc20 (62). However, Pines’ group questioned the auto-
ubiquitination of UbcH10. They reported UbcH10 didn't show a rate-limiting role in 
mitosis towards APC substrate destruction. Instead they find that it is rate-limiting in late 
G1 phase where UbcH10 is required to destabilize Cyclin A and prevent premature DNA 
replication (63).  
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Aims of the Study 
 
The aim of this dissertation study was to gain a deeper understanding into how 
APC3 recruit substrate co-receptors: Cdh1 and APC10. Therefore, I studied their 
interactions through both a hybrid APC3 structure and biochemical assays. In Chapter2, I 
determined the structure of the hybrid APC3 protein (a chimeric APC3) to gain further 
insights into how Cdh1 and APC10 were recruited by APC3 through their highly 
conserved C-terminus (IR-tails). The APC EM-derived structures of APC subunits 
(APC7, APC3, APC6, APC8) were also used to check the authenticity of an interaction 
model (of the IR-tails and APC3) from the structural studies. In Chapter 3, I performed 
biochemical assays to understand how Cdh1 mediates the interactions with other APC 
subunits. Chapter 4 serves as an overview and a discussion on the future implications of 
these studies. 
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CHAPTER 2. CRYSTALLIZATION AND STRUCTURE DETERMINATION OF 
THE C-TERMINAL APC3: INSIGHTS INTO THE RECRUITMENT OF THE 
APC CO-ACTIVATORS AND APC10 BY APC3 
 
 
Crystallization Strategy 
 
Previous studies from multiple laboratories have shown that APC co-activators 
and APC10 are recruited to APC3 through their C-terminal highly conserved IR-tail 
peptides (33, 34, 36, 37).  It is known that the APC3 C-terminal domain is responsible for 
recruiting APC co-activators and APC10, but there are no structural models to elaborate 
details for the interactions.  This chapter mainly focuses on the crystallographic 
approaches to understand the mechanism of co-activator and APC10 recruitment by 
APC3. 
 
The crystallization attempts of APC3 full-length protein and domains +/− co-
activators/APC10 have been tried and none of them succeeded. When the atomic 
structure of N-terminal E. cuniculi APC3 was published (35), a strategy was developed 
by us to pursue the structure of human APC3 C-terminal domain by making hybrid E. 
cuniculi-human APC3 proteins. This hybrid protein idea was first reported to be a hybrid 
LRR (leucine rich repeat) technique and successfully applied to crystalize human TLR4 
(Toll-like receptor), a member of the LRR family (64, 65). Recently the hybrid technique 
also successfully crystalized internalin B, another member of the LRR family (66). This 
hybrid strategy is to facilitate soluble expression and the crystallization of the protein of 
interest, by replacing an insoluble domain of the protein with a corresponding domain of 
a homologue. The substitute domain is more soluble and structurally similar to the 
domain that will be replaced. Similarly, the principle of our strategy is to facilitate human 
C-terminal APC3 crystalization through fusing it to another protein that has a high 
probability to crystalize. 
 
Similar to E. cuniculi APC3, human APC3 is a TPR subunit with 14 predicted 
TPR motifs, and N-terminal TPR1-4 mediates homo-dimerization (35). Human APC3 has 
270 residues predicted disordered between TPR4 and 5, whereas E. cuniculi APC3 only 
has 20 residues in the corresponding disordered region. The large disorderd region 
accounts for almost 1/3 of human APC3 protein sequence and it is a hindrance to the 
crystallization. In addition, human APC3 is a highly hydrophobic protein and the full-
length protein easily aggregates during in vitro purification once the affinity/stabilizing 
tags are removed. The co-purification of APC3 with its co-activators or APC10 could not 
prevent the protein aggregation.   
 
In order to increase protein crystallization potential and improve protein 
behaviors, two versions of the chimeric APC3 were constructed (Figure 2-1). The short 
version incoporated E. cuniculi APC3 TPR5-6 and the longer version includes TPR1-6, 
which includes all the crystallized domain in the published structure (35). Both versions 
fused E. cuniculi APC3 TPRs to human APC3 TPR7 to 14. 
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Figure 2-1. The crystallization strategy of the human APC3 C-terminal domain. 
 
Illustration of the hybrid strategy to construct the chimeric APC3. The goal of the 
strategy is to replace the crystallization hindrance domains of the human APC3 with 
crystallizable/soluble, homologous domains of E. cuniculi APC3. Two versions of the 
chimeric APC3 were generated from TPR5-6 or TPR1-6 of the E. cuniculi APC3 N-
terminal domain fused onto TPR7-14 of human APC3 C-terminal domain. The long one 
used N-terminal dimerization domain TPR1-4 and TPR5-6, whereas the short version 
only includes TPR5-6. The expression test of APC3 domains is shown on the top right, 
with each fragment fused onto a His6-MBP tag.  
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Results and Discussion 
 
 
The binding ability test of the chimeric APC3s 
 
To investigate whether the chimeric APC3a are able to recruit the APC co-
activators, I used a co-pulldown experiment to test its binding ability with Cdh1. The co-
pulldown results shows that both the long and short versions of the chimeric APC3 
poorly interact with Cdh1 (Figure 2-2), which implies they lost the binding abilities to 
Cdh1 in solution. The co-expression of the chimeric APC3s with Cdh1 failed to restore 
them to the “binding” status. The IR-tail mimicking, APC inhibitor TAME was also used 
to test the chimeric APC3 binding ability via NMR WaterLOGSY. In the WaterLOGSY 
experiment, a free ligand gives multiple peaks pointing downward in the spectrum. Once 
the ligand binds to proteins, the peaks flipped upwards. No interaction signal with the 
chimeric APC3s was observed from the TAME 1D spectra, whereas TAME binds to the 
human wild type APC3 as a part of APC3-APC7-APC16 complex (Figure 2-3). 
 
 
Improvement of bacterial expression of the chimeric APC3 
 
Although the chimeric APC3s didn’t interact with the APC co-activator Cdh1, we 
were still interested in knowing what caused the change to the protein function.  Both 
versions of the chimeric APC3 dramatically improved protein yield, solubility and 
reduced the amount of aggregation from their insect cell (Hi-5) expression. Both versions 
were purified through affinity chromatography, ion exchange and gel filtration, followed 
by robotic crystallographic screening. The short chimeric APC3 generated hits in 
conditions of 0.1M HEPEs pH7.5, 1.6MAmSO4, 2% Dioxane at room temperature 
(around 25°C).  
 
In order to determine the crystal structure of the chimeric APC3s, an experimental 
phase is required to calculate an electron density map. The electron density map presents 
a three-dimensional description of the electron density of the overall molecule structure 
and outlines the molecule surface. A good map will make atomic model building 
possible. Crystal diffraction data of high quality with phase information is key for the 
crystallography software to calculate high quality maps. The phase is an intrinsic defect 
in crystallography, because observed crystal diffraction is the summary of all the 
electrons in the molecule. Without correct phase information, the two-dimensional 
diffraction spots cannot be reconstituted back to three-dimensional coordinates to outline 
the molecular envelope.  Generally there are two ways to get phases: one is through 
experiments (experimental phases) and the other is through homologous or predicted 
models.  During the structure determination of chimeric APC3, I tried varous models 
from published atomic models to synthetic models, and none of them was sufficiently 
accurate to generate a reasonable map.  This fact indicates the chimeric APC3 structure is 
significantly different than the existing models tried. 
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Figure 2-2. Test the chimeric APC3 binding ability to Cdh1 by a co-pulldown. 
 
(a) Flow chart to demonstrate the procedure of the co-pulldown experiment to test APC3 
binding ability with the Cdh1. APC3 were co-expressed with the Cdh1 and Cdh1 
substrate peptide Hsl130-2xStrep in insect cell Hi-5 strain. The co-pulldown was 
performed on the Strep tag of Hsl130. The amount of the APC3 co-eluted with Cdh1-Hsl30 
was used to indicate their binding ability.  
(b) SDS-PAGE to examine the co-pulldown results of (a). Four APC3 constructs were 
tested the binding ability with both the Cdh1 full-length and WD40 domain. APC3ΔL: 
Disorder region between TPRs 4 and 5 deleted. Two versions of the chimeric APC3: 
human APC3 TPR 7-13 was fused with E. cuniculi APC3 TPR1-6 (long version) or TPR 
5-6 (short version), respectively. FL: full-length protein. WD: WD40 propeller domain, 
the Hsl130-2xStrep peptide-binding domain. Molecular weight standards are labeled on 
the left side of the gel and protein bands are labeled with their names and construct 
schematics. 
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Figure 2-3. Examine the chimeric APC3 binding ability with APC inhibitor via 
1D WaterLOGSY. 
 
(a) Illustration of compounds TAME and AAME. Groups of each compound are 
illustrated in green color. 
(b) Schematic diagram of WaterLOGSY basic principle. The red rectangles and blue 
triangles represent non-binding and binding ligands, respectively. Green spheres 
represent water molecules. Non-binding ligands only receive magnetism transferred from 
unbound water, whereas binding ligands will also receive magnetism transferred from 
target proteins via bulk water molecules. In the 1D spectrum, both non-binding and 
binding ligands give positive signals (upward peaks). In the WaterLOGSY spectrum, the 
signals from the binding ligands remain positive and signals of the non-binding ligands 
becomes negative (downward peaks).  
(c,d) One-dimensional WaterLOGSY spectrum recorded of APC3 interaction with 
TAME (b) and AAME (c). The three spectra from top are the protein reference spectra of 
2µM chimeric APC3, 2mM Cdh1-Hsl130-Strep, and 2µM APC3-APC7-APC16, and one 
compound only reference of 0.2mM compound TAME (b) or AAME (c) at the bottom. 
The following three spectra from the top are the corresponding 2µM protein complexes in 
the presence of 0.2mM TAME (b) or AAME (c). The spectra were acquired with 10920 
scans and protein signals were destroyed with the design of WaterLOGSY pulse 
sequence. 
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Figure 2-3. (Continued). 
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Another common approach to obtain experimental phases is through the 
diffraction that is derived from heavy atom labeled crystals. Theoretically, the covalently 
attached heavy atoms will slightly shift the crystal diffraction pattern without affecting 
the overall intensity. Then the crystallography software is able to calculate the map 
through the anomalous signals. Selenomethionine substitution is a common way to 
incorporate selenium into protein peptides and label protein crystals. The principle is to 
use selenium labeled methionine to substitute normal methionine in the bacteria culture 
for the cells expressing proteins to be studied. To make that method applicable, I 
reconstituted the expression construct of the chimeric APC3 for bacterial expression, 
followed by the expression test in various bacterial strains.  In summary, the protein 
could be expressed in several strains but has a 10-fold lower yield, which could not meet 
the needs of the protein amount required for crystallization. In order to overcome this 
barrier, different affinity tags including GST, His-MBP, GST-MBP, GST-EGFP and 
GST-T4 Lysozyme, the chimeric APC3 mutants and the chimeric APC3 of different 
species were used to enhance protein expression.  Of the entire search, the GST-MBP tag 
with the wild type chimeric APC3 increased the protein expression 5-fold in bacterial 
strain BL21 gold (Figure 2-4). The final yield of GST-MBP tagged chimeric APC3 (in 
vitro purified protein) was 2.6 mg per liter culture, whereas the His-MBP tagged fusion 
only produced 0.55mg per liter. The purified chimeric APC3 behaves as well as the one 
purified from insect cells and generated crystallography hits in a similar condition at 
room temperature.  
 
 
Purification improvement of seleno-methionine labeled protein 
 
The selenomethionine (SeMet) substitution requires enriched media for bacteria 
growth, which benefits the protein expression. However, the E. coli 60kDa chaperonins 
were also enriched during the purification of SeMet incorporated protein. The 
chaperonins accounted for 50% of final product (Figure 2-5). These co-purified 
chaperonins were identified by mass spectrometry.  
 
The chaperonins were reported to improve protein folding and they are driven by 
ATP hydrolysis. ADP stabilizes the chaperonins binding to its substrates, while ATP 
modifies its tertiary structure and promotes the chaperonin complex releasing the 
substrates (67). The co-purification of chaperonins with the chimeric APC3 suggested 
that they bind to the chimeric protein tightly. In order to separate APC3 from 
chaperonins, I included two-rounds of ATP incubation during the affinity 
chromatography and the incubation effectively removed the chaperonins (Figure 2-5). 
The selenomethione incorporation was confirmed by intact mass spectrometry. Each 
selenomethione has ~47Da more molecular weight than methione. Through comparing 
the molecular weight shift between SeMet protein and native protein, 10 selenomethiones 
were calculated that were incorporated into chimeric APC3 (Figure A-1). 
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Figure 2-4. Bacterial production of the chimeric APC3 is improved by a GST-
MBP tag.  
 
The schematic map of the chimeric APC3 construct (top), and SDS-PAGE of the 
chimeric APC3 protein purified from GST-MBP and His-MBP affinity tags. Proteins in 
both lanes were loaded with the same amount of affinity chromatography elutions.  
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Figure 2-5. ATP incubation efficiently removed Chaperonin during the chimeric 
APC3 purification. 
 
The schematic map of the chimeric APC3 construct (top), and SDS-PAGE of the purified 
chimeric APC3 protein purified with or without ATP incubation (bottom).  The ATP 
incubation removed the E. coli Chaperonin (blue gel) that was presented in the previous 
purification (gray gel). E. coli Chaperonin were identified by mass spectrometry.  
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Diffraction improvement and structure determination 
 
The diffraction of the chimeric APC3 crystals started at 8Å and it was improved 
to 3Å after multiple rounds of optimization. The low resolution didn’t have enough 
diffraction information to provide an accurate electron density map. A high mosacity 
value was also present in the higher resolution dataset, which indicates the dataset has 
multiple overlapped crystals and crystallography software could not calculate the correct 
map. This problem also exists in the SeMet crystal dataset, which leads to SeMet crystal 
dataset failing to generate experimental phase. Many approaches were tried to improve 
the mosacity, including screening at different temperatures, new crystals forms searching 
and optimization, heavy atom soaking and co-crystallization, seeding, TAME soaking, 
additive screening (Table 2-1). During the optimization process, the short version 
chimeric APC3 crystallized in multiple crystal forms (Figure A-2) and around 800 
crystals in total from different crystal forms were harvested. All the crystals were shot at 
synchrotron for data collection. Eventually, the combination of seeding, additives, and 
lower temperature (18°C) helped crystals grow to more than 10 times of the original size 
(Figure 2-6). The dissection of crystals into small pieces separated the overlapped 
multiple crystals and a good-quality dataset was obtained for structure determination 
(Figure 2-7).  
 
The atomic structure of the chimeric APC3 was determined by means of SAD 
(Single-wavelength anomalous diffraction) phasing from a SeMet dataset of 3Å. Data 
collection and refinement and statistics are summarized in Table 2-2. 
 
 
Structural analysis of the chimeric APC3 atomic structure 
 
The chimeric APC3 consists of 16 α-helices, with 14 of them in helix-turn-helix 
(TPR) motif. Based on the structure superimposition and sequence alignment, 14 anti-
parallel helices are TPR5-10 and TPR12, and they match the predicted TPR motif 
boundaries from APC3 secondary structure prediction from TPRpred and Psipred 
(Figure 2-8a) (68, 69). Each TPR motif was then assigned to an a and a b helix, with the 
a-helices lining the inner concave surface and the b-helices forming the outer convex 
surface. There are two α-helices: α-11 and α-13 are not in any predicted TPR motif. The 
helix α-11 is flanked by two loops and it breaks the successive TPRs pattern by folding 
back to the concave surface around TPR8-10 (Figure 2-8b). α-13 is a long α-helix 
following TPR12 and projects towards N-terminal TPR5. The loop-α-11-loop and α-13 
are within the regions of predicted TPR11 and TPR13 domains, respectively, but neither 
folds into the canonical TPR (Figure 2-8a). The TPR proteins of APC complex were 
expected to form a superhelix with their consecutive TPRs as the tertiary structure (20). 
However, the overall shape of the chimeric APC3 molecule does not display this 
superhelix structure.  
 
To interpret the folding mechanism, the chimeric APC3 structure was 
superimposed with E. cuniculi APC3 N-terminal structure and human APC3 predicted   
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Table 2-1. Summary of optimization approaches to improve the chimeric APC3 
crystal diffraction.  
 
 
  
Approaches Description/Summary Temp Result 
Addtive screening 110 additives screened 4°C & 
RT 
Best diffraction 
at 3.5Å 
Manually seeding 120 conditions manually seeded RT Diffraction 
around 4-5Å 
Robotic seeding-
screening 
1,300 conditions robotically screened 
with crystal seeds 
4°C & 
RT 
Generate hits in 
new conditions 
for optimization 
Heavy atoms co-
crystallization 
Co-crystallized with heavy atoms of 
Hg, Pt, (NH4)2SeO4 and lanthanides at 
1mM and 10mM 
RT No crystals 
Heavy atoms 
soaking 
Crystals soaked with 1mM or 10mM 
Hg, Pt, Au, Pb, (NH4)2SeO4 and 
lanthanides within pH range 6.5-7.0 
RT Best diffraction 
at 4-5Å, but no 
anomalous 
signal 
Low melting (LM) 
agarose growing 
Crystallization in 36 optimized 
conditions with 1% and 2% LM 
agarose 
RT No crystals 
TAME soaking 20 crystals soaked in 10mM TAME 
within pH range 5.5-8.5 
RT Diffraction 
around 4-5Å 
Cryo buffer 
screening 
30-40 cryo buffers tested during 
crystal harvest 
RT Best diffraction 
at 3Å 
MBP fused 
chimeric APC3 
Robotic screen around 1,300 
conditions, followed by manual 
screening with 120 additive for 
optimization 
4°C & 
RT 
Diffraction 
around 8Å 
T4 Lysozyme and 
EGFP fused 
chimericAPC3 
Robotic screen around 3,000 
conditions 
4°C & 
RT 
No crystals 
Lys-methylated 
chimeric APC3 
Robotic screen around 2,000 
conditions 
4°C & 
RT 
Pom-pom shape 
crystals 
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Figure 2-6. Original hits and improved crystals of the SeMet incorporated 
chimeric APC3. 
 
The crystals display the initial hits of the chimeric APC3 (left) and manual optimizated 
hits (right). The initial hits grow in 0.1M MES pH6.5, 1.6M (NH4)2SO4, 10% (v/v) 
Dioxane, RT. The optimization hits grew in 0.1M MES pH6.5, 1% Dioxane, 1.45M 
AmSO4, 2% MPD, 0.2M MgCl2, 0.1M Li2SO4, micro seeding 1:1000 at 18°C, seeded 
from native crystals. 
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Figure 2-7. Representative electron density. 
 
Final 2Fo–Fc electron density map contoured at σ1.4 is shown over the chimeric APC3 
structure. The blue mesh represents the calculated electron density map from the 
collected data and the yellow sticks indicate the peptide backbone, with oxygen atoms 
labeled in red and nitrogen atoms labeled in blue (70). 
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Table 2-2. Structure data and refinement statistics of the chimeric APC3. 
 
Statistics Chimeric APC3 (SeMet) 
Data collection  
Beam line APS 24-ID-C 
Wavelength (Å) 0.9793 
Space group C121 
Cell dimensions  
a, b, c (Å) a=235.5, b=130.1, c=103.9 
α, β, γ (˚) α=90, β=110, γ=90 
Resolution (Å) 80-3.0 
Total reflections 303819 
Unique reflections 111550 
Rmerge (%) 11.4 (75.1) 
Average I/σ  12.2 (2.0) 
Completeness (%) 97.9 (75.5) 
Redundancy 4.2 (2.1) 
Wilson B-factor 23.47 
Refinement  
Resolution range (Å) 50-3 
No. of reflections (σ≥0) 57195 
Rwork (%) 22.24 
Rfree (%) 25.49 
Number of protein atoms 15930 
Number of waters 43 
Average B-factor (protein) 55.31 
Average B-factor (water) 34.21 
RMSD: 0.012 
Bond lengths (Å) 1.216 
Ramachandran plot statistics  
Residues in preferred regions (%) 98.03 
Residues in additional allowed regions (%) 1.82 
Residues in disallowed regions (%) 0.15 
 
Highest resolution shell is shown in parenthesis. Rwork=(|Fo-Fc|/(Fo. Rfree is the 
crossvalidation of R-factor, with >5% of the total reflections omitted during model 
refinement. 
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Figure 2-8. Analysis of the chimeric APC3 structure through sequence and 
structural comparisons.  
 
(a) Multiple sequence alignment of human APC3 homologs. The residues that match 
human APC3 sequence are highlighted in yellow. Position of observed TPR motifs and 
α-helix elements are labeled with salmon color, whereas predicted TPR motifs are in light 
green.  
(b) Superimposition of the chimeric APC3 (salmon) onto a predicted APC3 C-terminal 
domain in light green.  TPR8-10 superimpose closely onto the predicted model. Other 
TPR motifs aligned less well with the predicted motifs in light green.  
(c) Superimposition of TPR 5-6 of the chimeric APC3 structure onto TPR 5-6 of E. 
cuniculi APC3 model. E. cuniculi APC3 residues 175-241, corresponding to TPR5-6 
adopts identical folding in both structures.  
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Figure 2-8. (Continued). 
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model, with reference to APC3 sequence comparison across eukaryotic species. The 
TPR5 and 6 in the chimeric APC3 were well aligned onto their TPR5 and 6 in E. cuniculi 
APC3, with an r.m.s.d of 0.5Å (Figure 2-8c), which means the TPR5 and 6 of the 
chimeric APC3 kept the same folding as in E. cuniculi APC3. The following TPR7 forms 
two shorter α-helices in the chimeric APC3 instead of the predicted canonical TPR7 
helices. The loops following helices TPR7a and TPR7b, instead, are longer than the 
prediction. Two α-helices of TPR7 spread across the concave and convex surfaces of 
TPR array instead of packing parallel to TPR8 (Figure 2-8b). The sequence boundaries 
of TPR8, 9 and 10 from the chimeric APC3 perfectly match their corresponding TPRs in 
prediction, and two structures of TPRs 8-10 are well aligned with an r.m.s.d of 1.46Å 
(Figure 2-8a, b). 
 
One unexpected mis-folding region is helix α-11, which corresponds to the 
predicted TPR11 domain but folds into a short helix, and flanked by two longer loops. 
The predicted TPR11 parallel TPR10, and extends the α-helices along the TPR array to 
form a superhelix. However, the helix α-11 slides into a concave surface that is lined by 
the helices a of TPR 8-10 (Figure 2-8a, b).  The flanking loops triple the length of a 
predicted turn between two antiparallel helices. The orientation of the following TPR12 
seems to be affected by the mis-folding of TPR11, although each TPR12 helix matches 
the expected boundary. TPR12 is packed in a perpendicular angle to TPR10 and breaks 
the pattern of the TPR arrangements (Figure 2-8b). Another affected region is the helix 
α-13, which also forms within the expected TPR13 domain.  α-13 adopts a long α-helix 
structure rather than two short anti-parallel α-helices. α-13 is parallel to TPR12 and is 
also perpendicular to TPR10. Meanwhile, the fact that α-13 extends towards TPR5 make 
the overall structure a globular shape, which may explain that the chimeric APC3 have 
higher solubility than most other in vitro purified APC TPR proteins. 
 
 
Identify human APC3 C-terminal binding groove through model comparisons 
 
In order to examine whether the structure of the chimeric APC3 is functional, The 
Dali server was used to search structurally similar TPR proteins through three-
dimensional structure analysis. TPR7-12 domain of the chimeric APC3 was used as the 
search model, and three hits: Carboxyl terminus of Hsp70-interacting protein (Chip), and 
TPR9-11 of human APC6 and yeast APC6 all have highest structurally similarity with 
human APC3 TPR8-10. All the models were superimposed onto APC3 TPR8-10 with an 
r.m.s.d smaller than 1.1Å and the helix α-11 of the chimeric APC3 overlapped with all 
the peptides (binding partners) of three similar hits (Figure 2-9).  
 
The structural superimposition suggests that the highly conserved TPR8-10 in the 
chimeric APC3 adopts canonical TPR protein folding (Figure 2-8a, Figure 2-10a) and 
structurally it is also highly similar to three peptide-interacting domains (from the hits). 
Beside, the mutagenesis study reported that the mutation (N581A/L612A of helix 8a and 
9a) in this domain reduced Cdh1 association with APC with a decreased ubiquitination 
(34). All the above indicate TPR8-10 is the APC3 binding groove that is responsible for 
recruiting IR-tail peptides.  The helix α-11 is buried inside the binding groove and   
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Figure 2-9. Structural alignments of the chimeric APC3 with TPR proteins reveal 
a rigid binding groove and pseudo binding partner.  
 
The chimeric APC3 (salmon) is superimposed onto the TPR domains of Stub1 Chip 
(warm pink) and the TPR9-11 of S. pombe APC6 (olive). The cyan asterisks labeled the 
interacting peptides: Hsp90 (blue) and Cdc26 (cyan), which overlapped with the helix α-
11. 
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Figure 2-10. Pseudo binding partner α-11 interacts with two binding pockets in 
the APC3 binding groove. 
 
(a) Multiple sequence alignment of TPR8-10 motifs of human APC3 homologs. The 
bars above consensus indicate the conservation strength: red, invariant residues; 
orange: conserved residues. Red or orange triangle legends indicate the residues 
labeled out in the model of (b). Positions of observed TPR 8-10 are labeled with 
salmon color, which matched the predicted TPR 8-10 in light green.  
(b) Details of conserved residues at the inner face of the binding groove model (left) 
and their contribution to the surface charge (right). Left:  Invariant residues are 
colored in red and conserved residues colored in orange. Human Cdc26 N-terminal 
peptide was superimposed onto the helix α-11 position.  Right: The bar at the bottom 
right indicates the surface electrostatic potential. Two binding pockets at the binding 
groove surface are outlined with green (negatively charged pocket) or cyan 
(hydrophobic pocket) dash lines.  
(c) Close-up views of the key interactions between pseudo binding partner helix 
(light-pink ribbon and sticks) and two binding pockets (surface and sticks). The α-11 
residues interacting with the binding groove were displayed in pink sticks.  Dotted 
lines indicate the electrostatic interaction and the hydrogen bond of Lys690 with 
Glu616 and Ser584, respectively. 
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overlapped with all three peptides from the hits, which suggests it folds into a pseudo 
binding partner for APC3 and blocked the IR-tail recruiting domain.  
 
 
Human APC3 binding groove has two conserved pockets at the inner surface, one 
negatively charged and the other hydrophobic 
 
As every cloud has a silver lining, the fact that the chimeric APC3 is self-locked 
by its mis-folded TPR11 implies the functionality of the binding groove. Meanwhile, the 
pseudo binding partner α-11 demonstrates the interactions that the binding groove 
potentially uses for recruiting IR tail peptides. Moreover, the chimeric APC3 structure 
also provides a clue for studying TPR protein folding mechanism.  
 
A sequence comparison of the APC3 binding groove (TPR8-10) reveals a striking 
cluster of sequence conservation. There are 39 conserved residues among a total of 96 
residues in the binding groove and 22 conserved residues locate on the inner surface 
formed from α-helices 8a, 9a and 10a (Figure 2-10a). The highly conserved TPR8-10 
probably is the reason that the binding groove folded correctly and independently in this 
structure without being affected by the mis-folded neighbor regions.  
 
Highly conserved residues Asn581, Leu585, Ser584, L585, Tyr608, Leu612 and 
Glu616 were mapped onto the molecular surface of helices 8a and 9a, with their side 
chains facing toward superimposed peptides Cdc26 (Figure 2-10b). The conserved 
residues form a pocket-like surface with strong negative charges. The pocket surface 
around Ser584, Glu616 is most negative. Lys690 of helix α-11 was recruited to this 
pocket through electrostatic interaction with Glu616 and hydrogen bonds with Ser584 
(Figure 2-10c). 
 
The second pocket-like region within the binding groove is formed through well-
conserved residues His615, Asn 642, Tyr645 and maybe a non-conserved Met649, with 
their side chains facing towards the helix α-11. His615 localizes on the helix 9a and the 
other three are mapped onto the helix 10a. The pseudo binding partner α-11 establishes 
multiple hydrophobic interactions with the second binding pocket through Val684, 
Ala687 and Leu688 (Figure 2-10c). His615 packs its imidazole group toward Ala687 
and L688 of helix α-11 and the side chains of Val684 and Leu688 point to Asn642 and 
Tyr645, respectively. The second pocket creates a hydrophobic microenvironment along 
the concave inner face of the binding groove.   
 
 
Validate human APC3 interactions with the IR-tails through mutations of the APC3 
binding groove 
 
To validate the interaction mechanism observed from the chimeric APC3 
structure, key residue mutations in the APC3 binding groove were constructed and 
expressed for the interaction assays. In order to have better behaviors of APC3 mutants 
and Cdh1, all the mutants were expressed and purified in the complex of human APC7-
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APC3-APC16, and Cdh1 was co-expressed with its high-affinity substrate Hsl130. Similar 
to the wild type APC3, all the APC3 mutants formed a stoichiometry complex with 
APC7 (Figure 2-11a, bottom panel), indicating that the mutated residues did not impair 
mutant interactions with APC7. Most mutants were defective in binding Cdh1 through 
co-pulldown experiment (Figure 2-11a, top panel), and only three mutants, 
Y608A/Y645A, H615A/Y645A and H615A/N642A/Y645A/M649A had no or opposite 
effects (Figure 2-11a, middle panel).  
 
In order to identify the most informative mutants, the WaterLOGSY was also 
performed on the complexes APC7-APC3mutnts-APC16. This approach is suitable for 
detecting binding affinity in the micromolar range (71), and thus it reveals more 
differences of the weak interactions. In the APC3 mutant WaterLOGSY experiment, the 
mutant of S584A/E616R directly affected the peaks 5 and 7, the interactions between the 
backbone of Arginine side chain and the binding groove. Peaks 5 and 7 disappeared in 
the mutant of S584A/E616R, and all other mutants that include these two mutations. This 
result matched the speculation that S584 and E616 mediate the salt bridge with the 
Arginine guanidinium group of the IR-tails (Figure 2-11b). Although salt bridge could 
not be directly detected by this approach due to their higher affinity, the disappeared 
interactions (of peaks 5 and 7) probably resulted from those missing interactions. 
 
The interactions from tosyl group (Peaks 1 and 2) and from the backbone of 
Arginine side chain were almost completely wiped out by another mutant of 
H615A/N642A/M649A. It confirmed that the H615, N642 and M649 together form the 
hydrophobic core and potentially directly interacted with the Isoleucine of the IR-tails. 
Although the residues S584 and E616 were still available to mediate salt bridge, the 
Arginine side chain failed to stay bound. This result indicated that hydrophobic 
interactions from Isoleucine of the IR tails stabilized the salt bridge formed by the 
guanidinium group.  
 
Other mutations of the binding groove showed more or less minor binding 
defectiveness towards IR-tails or TAME. The mutant of H615N/M649N lost the 
interactions with Cdh1 C-terminus in the co-pulldown but only had subtle effects on 
TAME (Figure 2-11a, c). However the mutant H615A/N642A/M649A became most 
defective to TAME when N642A mutation was incorporated. It seemed N642 was 
important for hydrophobic interactions of TAME, whereas the mutations of H615 and 
M649 were enough to disrupt the IR-tail interactions. TAME were reported as an APC 
inhibitor when Cdh1 was present (40, 51). Comparing to the Cdh1 IR-tail, it potentially 
mediated stronger interaction with APC3.  
  
The Y645A mutation seemed to have opposite effect on Cdh1 interaction and no 
effect to TAME binding (Figure 2-11a, c). The mutants of H615A/Y645A and 
H615A/N642A/M649A/Y645A tended to increased the Cdh1 interaction in the co-
pulldowns. The function of Y645 was not certain and the mutation of Y645A might 
create non-specific hydrophobic interactions. 
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Figure 2-11. Mutants of key residues inside the APC3 binding groove validated 
interactions between the APC3 and Cdh1 IR-tail. 
 
(a) Co-pulldown to examine APC3 mutants binding ability with Cdh1-Hsl130-2xStrep in 
the complexes of GST-APC7-APC3 (wild type or mutatns)-APC16. The co-pulldown 
was performed on the Strep tag of the substrate peptide Hsl30-2xStrep (top two panels) 
and GST tag of APC7 (bottom panel), separately. The top panel shows the defective 
APC3 mutants and the middle panel groups three mutants of subtle or no effects. APC3 
mutated residues in each co-pulldown are labeled on top of each lane, with APC3 and 
Cdh1∆C as controls in the left four lanes of each gel. ∆C: IR-tail deleted Cdh1; fl: full 
length Cdh1; wt: wild type APC3. All the bands marked by asterisks were identified by 
mass spectrum. The red asterisks mark the bands electrophoresed from the expected 
proteins. The yellow asterisk labels containment protein bands of Tublin beta-1, which 
co-migrated with Cdh1fl protein through SDS-PAGE. The green asterisk indicates the 
breakdown of Cdh1∆C. The spheres and triangles bellow the gels (top and middle panel) 
label the positions of the corresponding APC3 mutants in the WaterLOGSY spectrum (c), 
with triangles indicating the mutants of subtle or no effect towards TAME binding, and 
spheres marking the defective ones.  
(b) Structure illustrations of similarity of the compound TAME to the IR-tail (left), 
and APC3 binding groove surface (right). The groups/residues in TAME/IR-tail are 
labeled in green color, with numbers marking the corresponding proton signals/peaks 
of the WaterLOGSY spectrum (c). Blue and red colors represent the electrostatic 
potential of the binding groove surface as positive and negative, respectively. Two 
binding centers: a negatively charged and a hydrophobic pocket at the surface are 
outlined with green and cyan dashed lines, respectively. The cyan colored numbers 
(1,2,6) indicate the corresponding protons potentially interact with the hydrophobic 
pocket (cyan dashed lines), while the green numbers (5,7) suggest the proton signals 
(of the Arginine side chain) are potentially affected by the negatively charged pocket 
(green dashed lines).  
(c) One-dimensional WaterLOGSY spectrum recorded interactions of the APC3 mutants 
with TAME in the complexes of APC7-APC3mutants-APC16. All the spectra were 
scaled with the same magnitude. Three reference spectra include the top one of 2µM 
APC7-APC3wild type-APC16 with 200µM TAME and bottom two of 200µM TAME 
alone, and 2µM Cdh1-Hsl130 with 200µM TAME, respectively. The ten spectra in the 
middle are the 2µM APC7-APC3mutants-APC16 in the presence of 200µM TAME. The 
peaks labeled out by cyan, orange and green numbers are the signals of the protons in 
TAME, as labeled in (b). The cyan numbers (1,2,6) and green numbers (5,7) indicate the 
binding potentially affected by the mutants in the hydrophobic pocket (b, cyan dashed 
lines) and mutants in the negatively charged pocket (b, green dashed lines), respectively. 
The spectra were acquired with 10920 scans and protein signals were destroyed with the 
design of WaterLOGSY pulse sequence. 
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Figure 2-11. (Continued). 
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A hypothesis of APC3 recruiting the IR-tail and implication for future study 
 
The helix α-11 binds to the groove through one lysine (Lys690) and one Leucine, 
and they bind to two pockets with multiple interactions. Besides, these two residues are 
structurally close to each other (Figure 2-10c). Lysine is structurally similar to Arginine 
and Leucine is the isoform of Isoleucine. In addition, the binding pockets consist of 
highly conserved residues across species, especially the negatively charged pocket 
(Figure 2-10a). The sequence conservation indicates that hydrogen bonds, electrostatic 
and hydrophobic interaction are evolutionarily important to bind the IR tail. Lys690 and 
Leu688 of helix α-11 potentially mimic such interactions.  
  
The first/negative charged pocket is surrounded with four conserved hydrophobic 
residues: Leu585, Tyr608, Leu612, His615 and one polar residue: Asn581, mapped onto 
helices 8a and 9a. Potentially they stabilize the helix α-11 in the binding groove by 
contacting Leu683 and Ala687 of the helix α-11 through hydrophobic interactions 
(Figure 2-10c). APC3 mutant N581A/L612A affected the hydrophobic interaction with 
TAME (Ile-Arg mimic compound) mediated by Cβ, Cγ, Cδ of TAME Arg side chain. IR-
tail mutated to IK-tail leads to Cdh1 failing to associate with or activate APC (38). The 
protonated Arginine side chain has a pKa around 12.5 whereas Lysine’s pKa is 10.5. The 
positive charge of guanidino group is extensively delocalized, and it is able to establish a 
stronger noncovalent interaction than Lysine.  
 
Based on the above interaction analysis, a hypothetical model is proposed from 
this study (Figure 2-12). Arginine inserts into the first binding pocket, establishing 
hydrogen bonds with Ser584, and a salt bridge with Glu616.  Because of the large 
mobility of the Arginine long side chain, the interaction contributed from surrounding 
residues Asn581 and Leu612, potentially restrict its side chain. Isoleucine is recruited to 
the second binding pocket mainly through His615 and Tyr645.  
 
Biologically, the highly conserved residues of IR tails and APC3 binding groove 
indicate their interaction patterns are consistent for all species. IR tail deletion and 
mutation both reduced the co-activators affinity and their ability to activate APC. The IR 
tail interaction will anchor the co-activators and APC10 to the right location of APC3.  
Given the orientation change of the co-activators during the APC activity regulation and 
ubiquitination event (31, 32), its probably essential for the co-activators to be recruited to 
the correct location before being involved in substrate recruitment and poly-ubiquitin 
chain formation. The crystallographic model of APC3 with co-activators or APC10 will 
provide an accurate model to understand the interaction details.  Alternatively, it could 
also be obtained through small compound TAME docking into APC3 binding groove, 
followed by the experimental validation.  
 
 
TPR subunits models docking into APC EM map 
 
In the attempts to examine the authenticity of the APC3 binding groove model 
and study the APC assembly, APC negative-stain electron microscopy maps of the  
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Figure 2-12. A hypothetical model demonstrates IR-tail interacting with the APC3 
binding groove. 
 
A hypothetical model demonstrates the potential interactions between IR tail (green and 
cyan sticks) and APC3 binding groove (surface and sticks), with oxygen and nitrogen 
atoms of labeled residues in red and blue, respectively. The surface charge is identical as 
shown in Figure 2-10b. Dashed lines label the interactions of the salt bridge and 
hydrogen bond. 
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recombinant human APC and human APCCdh1-Emi1 (EMD 2226 and 2354) (23, 72)were 
used for generating TPR subunit models. The Itasser predicted models of TPR subunits 
and APC1 were used to initiate model docking (73). N-terminal and C-terminal domains 
of each TPR subunit model were docked in separately. The N-terminal TPR motifs 
mediate dimerization and they were docked in as a dimer (instead of monomers). The 
TPR1-4 of both APC3 and APC7 form homodimers, whereas the N-terminal 6 TPR 
motifs (TPR1-6) mediate larger dimers of APC6 and APC8. The TPR4 and 5 of APC3 
are separated by a disordered loop of about 270 residues, and the loop has no matched 
density on both EM maps. Moreover, the loops or short α-helices of each model were 
deleted if there are no matched densities. The binding groove of the chimeric APC3 
model agrees with the APC3 C-terminal predicted model with a superimposition r.m.s.d 
of 1.46Å (Figure 2-6a, b). Therefore, it is incorporated into the APC3 C-terminal 
predicted model for docking.  
 
The correlation coefficients of models generated from EM map docking are listed 
in the Table 2-3. EMD 2354 (23) is the map of complex APCCdh1-Emi1 and EMD 2226 
(72) is from the APC sample without Cdh1. The coordinates of human APC10 and Yeast 
Cdh1 propeller domain were used as references and they both have higher correlation 
coefficients of 0.89 and 0.92, respectively. The high correlation coefficients between 
docked models and their corresponding densities of the EM maps indicate a good fit 
between the TPR models and the EM map. 
 
EM-derived dimers of APC7, APC3, APC6 and APC8 dimerize through their N-
terminal domains and generate “V” shape molecules of all the APC TPR subunits 
(Figure 2-13). Each dimer has a unique overall shape with angles and dimensions 
different from others.  APC3 dimer has a mamxium dimension of 135 Å. Although there 
is a 270-residue loop separating TPR4 and 5, APC3 TPR motifs together with α-helices 
between TPR4 and 5 adopt a linear superhelix measuring 110 Å in length and 40 Å in 
diameter. 
 
All the prediction models are based on protein crystallographic or homologous 
modeling. N-terminal domains of human APC3 and APC6 are predicted based on the 
yeast APC6 atomic model (PDB code: 2XPI), whereas the human APC8 dimerization 
domain is based on the yeast APC8 structure (PDB code: 3ZNZ). The EM-derived 
dimerization domains of APC3 and APC6 have 0.4Å and 0.8Å deviation with their 
homologus model (yeast APC6), respectively, and APC8 N-terminal domain deviates 
around 0.4Å from the yeast APC8 structure. The atomic structure of human APC7 TPR1-
3 has been determined (PDB code: 3FFL), although the dimerization interface of the 
structure is biologically irrelevant. The model of APC1 PC repeats are predicted from 
26S proteasome subunit Rpn2, and its overall structure looks like a closed toroid of two 
concentric α-helical rings. The PC repeat consists of tandem copies of 35-40 amino acid 
repeat motifs, with each motif forming into α-helix-turn-α helix. 
 
TPR 1-4 of the EM-derived APC3 model were superimposed onto the 
corresponding TPRs of APC6, E. cuniculi APC3 and APC8 structures with r.m.s.d of   
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Table 2-3. Correlation coefficients of EM-derived TPR structures to APC EM 
maps.  
 
The models of EM docking 
Correlation 
coefficient in 
APCCdh1-Emi1 EM 
map (EMD 2354) 
Correlation 
coefficient in APC 
EM map (EMD 
2226) 
APC7 N-terminal dimer (TPR1-4) 0.87 0.859 
APC3 N-terminal dimer (TPR1-4) 0.8865 0.8868 
APC6 N-terminal dimer (TPR1-6) 0.8983 0.9043 
APC8 N-terminal dimer (TPR1-6) 0.8415 0.862 
APC7 C-terminal domain (TPR5-C) 0.8337 0.8745 
APC3 C-terminal domain (TPR5-C) 0.8706 0.858 
APC6 C-terminal domain (TPR7-C) 0.8311 0.8926 
APC8 C-terminal domain (TPR7-C) 0.8507 0.7949 
APC1 PC repeats 0.8452 0.8131 
APC10 (PDB code: 1JHJ) 0.8951 0.8905 
Cdh1 (PDB code: 4BH6) - 0.9182 
Cdh1 with substrate KEN box and D box 
(PDB code: 4BH6) 
- 0.9242 
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Figure 2-13. TPR subunits form elongated V-shape homo-dimers in the human 
APC assembly.  
 
APC7, APC3, APC6, APC8 all form “V”-shaped homo-dimers and assemble in parallel 
in a hierarchical fashion to build the arc lamp (TPR arm) of the human APC. All the 
models are predicted by Itasser and adjusted based on the APCCdh1-Emi1 EM map (EMD 
2354) (23). The more globular dimerization modules form the apex of the ‘V’, and the 
narrower C‐ terminal TPR superhelices project away from the dimer interfaces.  
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0.6Å, 2.2Å and 1.8Å, respectively. Additionally, the TPR1-4 in APC3 and APC7 
structure (PDB code: 3FFL) are 2.8Å deviated from each other (Figure A-3). The first 
four TPR motifs in all EM-derived structures all adopt canonical folding and are similar 
to each other. The following secondary structures, TPR5-6, has different orientation and 
helix length among four TPR subunits and could not be aligned (Figure 2-14a, b). The 
C-terminal TPR motifs make the differences among V-shape dimers of four TPR subunits 
(Figure 2-13). 
 
All the TPR subunit dimerization domains localize at the backside of APC 
complex, where all TPR proteins assemble into the TPR arm. The atomic fitting of the 
TPR subunits to the EM map accounts for the major density of the TPR arm (more than 
90% of the density), and rationalized its repetitive layered architecture. Two copies of 
APC3 TPR5-14 spiral along two opposite directions to the front side of the APC, where 
Cdh1 and APC10 contact APC3 (Figure 2-14c). Each co-receptor (Cdh1 or APC10) is 
attached to one copy of the C-terminal APC3, respectively. In the EM-derived structures 
of the APC3 C-terminal TPR5-14, TPR8-10 is contributed from the chimeric APC3 
atomic model. All the α-helices present in the predicted models match the secondary 
structure prediction (Figure 2-6). 
 
Although the C-terminal IR tail peptides of both Cdh1 and APC10 atomic 
structures are absent, EM maps demonstrate additional electronic densities which extend 
from the C-terminal end of APC10 β-barrel folds. The densities connect APC10 to the 
APC3 binding groove TPRs (TPR8-10) and it ends at the docked IR-tail model inside the 
groove (Figure 2-14d). Potentially these densities are contributed from the C-terminal 
peptides of APC10. The distance between APC10 model C-terminus and Ile of the IR-tail 
model is around 30-40Å, and 20 residues of C-terminal APC10 will be more than enough 
to bridge this distance.  
 
 
Implication of the C-terminal APC3 alternative folding 
 
The chimeric APC3 self-lock is an interesting phenomenon during the protein 
folding. In order to explore the mechanism that accounts for this phenomenon, the APC3 
sequence flanking the binding groove was analyzed through the comparison between 
EM-derived model and the chimeric APC3 model in the corresponding domains. For 
most canonical TPR proteins, the packing between α-helices requires intra-helices 
interaction (20, 26, 27, 35, 37). In the EM-derived model, five residues —Val676, 
His680, Ile681, Val683 and Val684 — of the helix 11a (TPR11a) are involved in 
mediating such intra-helices interaction (Figure 2-15a, left) with the hydrophobic 
residues Tyr, Phe and Leu of TPR10. These hydrophobic interactions maintain the helix 
11a packing in parallel to TPR10. However, this canonical folding pattern is disrupted in 
the chimeric APC3 model (Figure 2-15a, right), where residues Val683, Val684, Ala687, 
Leu688 and Lys690 interact with the binding groove and mediate the formation of the 
helix α-11.  
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Figure 2-14. Models of TPR subunits docked into the negative-stain EM map of 
the human APCCdh1-Emi1 complex. 
 
(a, b) The comparisons of EM-derived N-terminal models (TPR1-6) of human APC3, 
APC6 and APC8, with E. cuniculi APC3 N-terminal structure (a, PDB code: 
3KAE)(a) and S. pombe APC8 N-terminal model (b, PDB code: 3ZNZ). The α-
helices are displayed with the shapes of cyclinders in (b).  
(c) Two stereo views showing the APC models closely fit in the molecular envelope 
of APCCdh1-Emi1 complex (EMD 2354) (23).  
(d) Details of the interactions between APC3 and C-terminal APC10. The model of 
human APC10 is used for docking, with a red asterisk indicating its C-terminal end. 
The hypothetical IR tail interaction model (Figure 2-12) is incorporated into the EM-
derived APC3 structure, and together they are docked into the APCCdh1-Emi1 EM map. 
The model of the IR tail is showed as cyan sticks, with the interacting residues 
labeled in red and orange sticks as showed in Figure 2-11. The black arrow points at 
the density contributed from APC10 C-terminal unstructured peptides, with the dot 
line representing its possible orientation. The red asterisk indicates C-terminal end of 
APC10 β-barrels.  The corresponding APC10 sequence to the labeled density is 
marked out with dotted lines at bottom. The unstructured C-terminal peptides of 
APC10, Cdh1 and Cdc20 all have similar number of residues.  
 
  
 57 
 
 
 58 
 
 
 
 
Figure 2-14. (Continued).  
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Figure 2-15. The binding groove of human APC3 affects TPR11 adopts a canonical 
folding. 
 
(a) Views of TPR11 folding in EM-derived model (left panel) and the chimeric APC3 
structure (right panel). The binding grooves (TPR8-10) are presented as surface density. 
Purple labeled residues mediating TPR11 packing in parallel with TPR10 (left) while 
they are in a disordered loop in chimeric APC3. Pink color denotes the residues that 
theatrically stabilizing the TPR11a (left) but mediating α-11 formation in the chimeric 
APC3 (right).  
(b) Multiple sequence alignment at TPR10-11 motifs of human APC3 orthologs. The 
blue bars above consensus indicate lower conservation strength than the red and orange 
bars. (Red, invariant residues; orange: conserved residues). The purple and pink 
diamonds denotes the residues that are colored or labeled out by sticks (with the same 
colors) in (a). Position of the chimeric APC3 TPR 10 and α-11 are colored in salmon, and 
TPR10 and 11 in EM-derived APC3 model are labeled in green.  
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It is important to understand what triggers TPR11 folding into a pseudo binding 
partner instead of a canonical TPR motif, since no literature reports APC3 or TPR protein  
self-lock phenomenon. The sequence of APC3 TPR11 shows it is relatively less 
conserved compared to the sequence of other APC3 C-terminal TPR motifs (Figure  
2-15b, Figure 2-10a, Figure 2-8a). This may suggest that this region is less stable in 
adopting the canonical TPR motifs. Meanwhile, the fact that TPR11 folds into another 
helix (α-11) inside APC3 binding groove also indicates that the binding groove is capable 
of mediating strong hydrophobic interactions. Combining the above two aspects together, 
it seems human APC3 needs assistance from other domains or proteins to maintain 
canonical TPR protein folding.  
 
In addition to non-canonical folding of TPR11, TPR7 in the chimeric APC3 
structure doesn’t keep canonical folding either. Instead it folds into a short helix-long 
loop-short helix secondary structure. The EM-derived APC3 model provides a clue to 
interpret the mechanism of the human APC3 canonical folding. The TPR7 of the EM-
derived model is parallel with TPR6b. To study the factors that leads to this alternative 
folding, the interaction between TPR6 and TPR7, and protein sequence comparison are 
examined. The stereoviews of canonically folded TPR6 and 7 from the EM-derived 
model display the interactions between them (Figure 2-16a). The packing of helix 7a 
(TPR7a) to the helix 6b (TPR6b) is mediated through four conserved residues R532, 
F528, E525, Y521 of the helix 6b, with one residue assigned to one turn of the helix and 
lined up to face towards TPR7a (Figure 2-16a, left). Two of the four conserved residues: 
Arginine and Phenylalanine are the same as the E. cuniculi APC3 TPR6b at the 
equivalent positions (Figure 2-16b). The other two residues, Glutamic Acid and 
Tyrosine, potentially stabilize the helix 7a through hydrogen bonds with Threonine (T548 
of TPR7a) and hydrophobic side-chain interactions with Histidine and Leucine (H551, 
L552) at the last turn of the helix 7a. However, Glutamic Acid and Tyrosine (E525, 
Y521) are not present in the TPR6 of E. cuniculi APC3. The disrupted interactions 
potentially cause the lost the canonical TPR folding of the helix 7a. Instead it becomes a 
loop in the structure, with Histidine and Leucine (H551, L552) exposed in the solvent 
(Figure 2-16a, right).  
 
Unlike the TPR11, there is no other contact to TPR7 from other helices inside 
APC3 or other subunits of APC (demonstrated through EM map docking). It seems that 
TPR7 adopts correct folding in a TPR6-dependent manner, and TPR7 requires the whole 
set of conserved residues from its neighbor helix to stabilize its correct secondary 
structures. The sequence of both TPR7 and TPR11 are less conserved than those of the 
binding groove. Without the correct stabilizing interactions around TPR7, it forms into 
two shorter helices within the TPR motif boundary instead of a canonical α-helix-turn-α-
helix motif (Figure 2-16a).  
 
 
Biological meaning of APC3 folding and implication to future study 
 
The protein superhelical conformation was first discovered in Phosphatase 5 and 
it is believed to coordinate multi-subunit assembly (74). The canonically folded APC3   
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Figure 2-16. Human APC3 TPR7 folds in a TPR6-dependent manner. 
 
(a) Two stereoviews to demonstrate the interaction between the helices TPR6b and 
TPR7a in the EM-derived APC3 model (left), and the corresponding but disrupted 
interactions in the chimeric APC3 model (right).   
(b) The cross-species comparison of sequence corresponding to the TPR6 motif of APC3. 
Red residues are conserved in both the human and E. cuniculi APC3; orange and blue 
residues vary. The yellow highlights mark residues identical among different species.  
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adopts the right-handed superhelical structure. The superhelix makes it possible to 
establish new contacts among sequence distant helices.  
  
It is also interesting that the independently folded APC3 binding groove is flanked 
by two TPR motifs (TPR 7 and 11) whose secondary structures are sensitive to the 
proceeding TPR motifs and/or the tertiary structure. The human APC3 seems to require 
the whole C-terminal TPR domain (TPR5-13) to adopt and maintain the canonical 
folding. APC3 itself is located in a highly hydrophobic microenvironment (the TPR arm) 
that is created from all other TPR subunits. The inner surface of the binding groove is 
encircled by the superhelix of TPR5-11, which potentially repel unexpected helices 
interacting with the binding groove but keep the groove accessible for the unstructured IR 
tail peptides, or small molecules like TAME. Given that APC3 is sandwiched in the TPR 
arm by another two subunits: APC7 (top) and APC6 (bottom), it is probably critical to 
prevent the nonspecific interactions (from unexpected α-helices) locking the binding 
groove. Similar to APC3, APC6 also localizes in the hydrophobic microenvironment, and 
C-terminal superhelices of APC3 and APC6 have similar dimensions (Figure 2-17). The 
C-terminal APC6 accommodates the N-terminal peptide of Cdc26, which is the key to 
stabilize APC6 superhelical structure (26, 27). The APC3 superhelix potentially limits the 
space around the binding groove surface and this limited space is more accessible to 
peptides or small compounds than α-helices.  
 
Although the crystallographic model of the chimeric APC3 adopts a self-lock 
structure, it reveals reliable surface details of human APC3 binding groove, for further 
recruitment mechanism study. The self-lock structure also partially displays the binding 
groove mediated interaction. Being incorporated by the chimeric APC3 structure, the 
EM-derived model becomes a guide for further assay design to validate interactions of 
APC3 with the co-activators and APC10. This information could also benefit APC 
inhibitor, like the compound TAME, optimization to improve their affinity to the binding 
groove. Additionally, this model provides clues that allow speculation the role of APC3 
tertiary structure in maintaining its function.  
 
 
Crystallization attempts of APC TPR subunits 
 
Crystallizations of other APC TPR subunits were tried (approached), as listed in 
Table A-1. It includes the complex of the full-length proteins APC8-APC6-Cdc26 from 
different species, and a truncated APC3 in the complex of APC3∆L-APC16 with or 
without Cdh1. The full-length complex APC8-APC6-Cdc26 didn’t crystallize, but the 
APC3∆L-APC16 crystallized with or without Cdh1 (Figure A-4, Figure A-5). Both 
crystals showed the optimization potential by diffracting to 6Å and 7Å, respectively. 
Until the time this dissertation is written, they are still being pursued.  
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Figure 2-17. The superhelix structure limits the accessibility of the APC3 binding 
groove.  
 
Structural superimposition of S. pombe APC6 (yellow, PDB code: 2XPI) and EM-derived 
human APC3 (green) demonstrates that two structures have similar dimensions of 
superhelices. The docked IR tail model is showed as a cyan stick. Both IR tail and N-
terminal Cdc26 are buried inside the groove of the superhelices. 
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Materials and Methods 
 
 
Constructs for crystallization 
 
All the protein expression constructs were made by standard PCR/ligation 
procedures, and sequences were verified by automated sequencing procedures. The APC3 
deletion and mutation were designed with reference to the human APC3 830 a.a sequence 
isoform (uniprot code: P30260). The E. cucniculi APC3 sequence used for designing the 
APC3 chimeras refers to the reported one in (35) (uniprot code: Q8SQV4). The TPR7-14 
of the human APC3 refers to residues 539-830 of the full-length protein. TPR1-6 of E. 
cucniculi APC3 refers to residues 1-241 and TPR 5-6 refers to 175-241 of the parasite 
APC3 sequece. The chimeric APC3s were cloned to an N-terminal His6-MBP- tagged 
insect or bacterial expression vector, and a GST or GST-MBP tagged bacterial vector. 
 
The crystallization tags, including an enhanced green fluorescent protein (EGFP), 
a T4 lysozyme and a MBP-(AAA), used for crystallizing the chimeric APC3s were 
inserted between the N-terminal GST tag and the chimeric APC3. The EGFP residues 
1-230 were used for crystallization (uniprot code: C5MKY7), and the T4 lysozyme 
(uniprot code: P00720) was linked to the N-terminus of the chimeric APC3s with three 
Alanines residues, similar to the MBP-(AAA) tag. The MBP-(AAA) is the crystallization 
version of a maltose binding protein (PDB code: 3RUM_A). Alternative APC3 chimera 
constructs were the TPR7-14 of two yeasts and a worm APC3 fused to the E. cuniculi 
APC3 TPR1-6 and TPR5-6, respectively. The TPR7-14 of different species refers to the 
residues: S. pombe 397-665 (NCBI code: NP_594604.2), S. cerevisiae 506-758 (uniprot 
code: P38042), C. elegans 527-788 (NCBI code: NP_001021714). The chimeric APC3 
mutant refers to the mutations of V181K and I185D of the E. cuniculi APC3.  
 
The Cdh1 truncation and deletion constructs have been described in the Material 
and Methods of Chapter three. The human Cdh1, Cdc20 and APC10 C-terminal peptide 
(also named the IR-tail peptides) constructs were made by the above cloning procedure. 
The Cdh1 IR-tail peptide refers to the residues 479-496. Protein sequences of the human 
Cdc20 and APC10 are referred from Uniprot (uniprot code: Q12834, Q9UM13). The 
APC10 IR peptides have two versions: residues 161-185 and 171-185. The Cdc20 IR-tail 
peptides include residues 474-499. All of the peptides were fused to an N-terminal GST, 
His6-MBP-, and GST-MBP-(AAA) within the bacterial expression vectors.  
  
The bacterial expression vectors for the N-terminal GST-, His6-MBP-, GST-
MBP, or His6- fusions were from either a regular or modified version of pGEX4T1 (GE 
lifesciences), pRSF1b (Novagen) vectors. The insect cell expression vectors for the above 
fusions were constructed from the vectors pFastBac1, pFastBac-GST, and modified 
pFastBac-His6MBP (Invitrogen). 
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Protein expression and purification from bacteria 
 
The E. coli expression strains, BL21(DE3) Gold (Novagen), codon enhanced RIL 
(Stratagene) and Rosetta (Novagen) were used for expression tests of the protein 
constructs. Most of the large-scale protein production from the bacteria was done in 
BL21(DE3) Gold, with the cells cultured in LB broth Miller (EMD) supplemented with 
the appropriate antibiotics.  
 
The chimeric APC3 proteins were expressed from the bacterial vector pGEX-4T1 
(GE). The starter media was incubated at 37°C overnight in a rotary shaker at 200 
revolutions per minute (rpm). The overnight culture 10 ml was then used to inoculate into 
12L LB media that contains a final concentration of 200 μg/ml ampicillin. The 
BL21(DE3) Gold strain harboring the expression constructs were cultured at 37°C until 
reaching an OD600 of ~0.8. After cooling the media to 18°C for 1hr, the expression was 
induced by the addition of IPTG (isopropyl β-D-1-thiogalactopyranoside) to a final 
concentration of 0.6 mM, followed by overnight culture at 18°C. The next day, the cells 
were resuspended in a buffer of 50 mM Tris-HCl pH7.6, 0.3 M NaCl, 5 mM DTT, and 
supplemented with 2.5 mM PMSF, and lysed by sonication on ice. The GST-MBP tagged 
chimeric APC3s were purified by glutathione-affinity chromatography, and eluted protein 
fractions were treated with the homemade TEV protease at 4°C overnight at 1:50 ratio. 
The cleavage by TEV protease left 2 extra residues (Gly-Ser) on the N-terminus of 
proteins prior to the protein linker Glu-Phe-Ser-Gly.  
 
For co-crystallization, the chimeric APC3s were purified by Ion Exchange 
chromatography (IEC) to separate the cleaved affinity tags from the purified proteins, 
based on the isoelectric point difference.  IEC is done with a 5ml Hi-Trap column (GE) in 
a buffer of 50mM Tris-Cl pH 8.0, and the protein fractions were concentrated to 20-
40mg/ml (Bio-Rad Protein Assay), followed by a gel filtration chromatography. The gel 
filtration was performed to further remove contaminants based on the molecular shapes 
and sizes, using a Superose 6 column (GE) in a buffer of 50 mM Tris-HCl pH 7.6, 0.3 M 
NaCl and 5 mM DTT. After gel filtration, the remaining GST-MBP and uncleaved 
chimeric APC3 protein were removed with glutathione-affinity resins before the purified 
protein was concentrated to 20-25 mg/ml (A280 measured), aliquotted, flash-frozen in 
liquid nitrogen, and stored at -80°C until latter use. 
 
The Selenomethionine labeled chimeric APC3 was expressed in the BL21(DE3) 
Gold cells cultured in the autoinduction media. The cells grew in a 24L-culture at 37°C 
till they passed the exponential phase and then the temperature was reduced to 18˚C 
overnight for protein production.. The SeMet incorporated protein was purified through 
GST chromatography. Before the 10mM glutathione elution, a wash buffer containing 
25mM ATP was incubated twice with protein-bound glutathione sepharose/resins for 15 
mins/per wash, followed by the additional resin wash to remove the extra ATP. The 
elutions of the SeMet chimeric APC3 were applied the same purification procedure as the 
native protein. Following size exclusion chromatography, the protein was concentrated 
and stored in a buffer containing 50 mM Tris-Cl pH 7.6, 300 mM NaCl and 5mM DTT. 
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The protein concentration used for crystallography varied within the range of 12.5-25 
mg/ml (A280 measured). 
 
 
Crystal screening and optimization 
 
Crystallograhy screenings were performed using a Mosquito crystallization robot 
(TTP Labtech) with the commercial 96-well screens. Over 2,000 commercially available 
and homemade conditions were screened at 4°C and room temperature (RT), and one 
initial hit was found two days later in needle shaped clusters. This hit grew in the 
condition of 0.1M MES pH6.5, 1.6M (NH4)2SO4, and 10% (v/v) Dioxane at RT. All the 
robotic screening used the hanging drop vapor diffusion method against 100μl of well 
solution with a drop ratio 1:1 (200 nl protein: 200 nl well solution), with a protein 
concentration of 15-20mg/ml.  
 
To improve crystal size, manual screenings were performed using the ratios of 
1:1, 1:2 and 2:1 (1ul:1μl or 2ul:2ul, 1ul:2ul, and 2ul:1µl protein:well solution). Crystal 
drops were equilibrated by vapor diffusion against 500 μl-1ml of precipitant solutions at 
RT. Meanwhile, I optimized the screening around the initial conditions with different 
precipitant concentrations, different pH buffers, and different commercial and homemade 
additives under different temperatures, combining with the streak and micro seedings.  
The optimization screenings were summrized in the Table 2-3. The optimized condition 
of 0.1M MES pH6.5, 1.8M (NH4)2SO4, 2% (v/v) Dioxane and 2% MPD tripled the 
crystal size. Multiple rounds of cryo buffer screenings were performed to obtain qualified 
diffractions. More than 50 cryo buffers of 23 cryoprotectants were screened, and the best 
cryo-buffer is a buffer of 0.1M MES 6.5, 10% Dioxane, 1M AmSO4, and 6.5M Am-
formate. 
 
Another attempt to obtain high quality diffractions was to search new crystal 
forms. Around 1,000 commercial conditions were used as additives (10% commercial 
conditions +90% the optimized hit condition) and also as new precipitants (90% 
commercial +10% the optimized hit condition). MPD was screened out as a new 
precipitant that supports crystals rapidly growing larger (the crystals grew across a drop), 
in either long needle shaped clusters or thin plates. The optimized conditions of 0.1M 
MES 6.5/ 0.1M HEPEs pH 7.0/ 0.1M Bicine pH 8.0, 0.2M AmSO4, and 48-51% MPD 
generated SeMet and native crystals with a length of ~0.4mm and in a shape of long-
needles or thin-quadrilaterals.  Interestingly, the larger crystals were dehydrated and 
quickly dissolved within two minutes when exposed to the air. The flash-frozen crystals 
in the drop solution (50%MPD is a cryoprotectant) diffracted to 4Å but in an anisotropic 
diffraction pattern (a diffraction pattern of stripes instead of lunes).  
 
The further attempts focused on improving the diffraction quality of the SeMet 
crystals. The solution failed to be calculated at the beginning because of the complexity 
that is contributed from both 70 Selenium sites inside one asymmetric unit (ASU) and the 
overlapped crystal lattices. The streak seeding, macro-seeding and lower temperature (to 
slow down crystals growing) didn't help the crystals grow single. Eventually the single-
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lattice dataset was collected from a small crystal (~0.2mm) that was gently dissected 
from a 0.4mm long/large crystal, growing in the condition of 0.1M MES pH6.5, 1% 
Dioxane, 1.45M AmSO4, 2% MPD, 0.2M MgCl2 and 0.1M Li2SO4, micro seeded from 
native crystals in a ratio of 1:1000 at 18°C. 
 
During the phase information pursuit, alternative approaches including heavy 
atom co-crystallization and soaking were also applied. The co-crystallization is 
performed manually by setting the screenings with the mixture of the protein and heavy 
atoms. The soaking is to soak native crystals in different heavy atoms, combined with the 
optimization of crystallization or cryo buffers, temperatures and wash times to remove 
the background heavy atoms. The soaked crystals were harvested for data collection at 
APS (Advanced Photon Source) and ALS (Advanced Light Source), and collected 
diffraction data were used for the heavy atom incorporation analysis.   
 
 
Crystallization of the chimeric APC3 modified by reductive methylation 
 
Reductive methylation was applied to improve the solubility of the chimeric 
APC3 through dimethylation of all the surface-exposed lysines (75, 76). In order to get 
the complete methylation, the purified chimeric APC3 was thawed and dialyzed in a 
buffer of 50mM HEPEs pH7.5, 0.3M NaCl and 5mMDTT to replace the protein storage 
(Tris) buffer. Freshly prepared 1M dimethyl amine borane complex (DMAB) and 1M 
formaldehyde were gently added into the protein solution, with the amount of 20µl 
DMAB per ml protein and 40µl formaldehyde per ml protein. This mix was gently 
repeated once and the protein was incubated at 4˚C for 2 hours to be methylated. Then a 
final aliquot of 10µl DMAB per ml protein was added into the mixture to methylate the 
protein overnight. The methylation mixture was gel filtrated the next day with a 
Superose6 column in a buffer of 50mM Tris-Cl pH7.6, 0.3M NaCl, 5mMDTT to quench 
the reaction and remove the excess DMAB and formaldehyde. The elution was examined 
by SDS-PAGE and then was concentrated to 12.5-25 mg/ml (A280 measured), aliquots, 
flash-frozen in liquid nitrogen, and stored at -80°C. In order to confirm the protein 
methylation, one aliquot of the frozen protein was analyzed with Intact Masspectrometry 
to detect the protein mass changes contributed from the methyl groups. The chimeric 
APC3 had 6-7 Lysine methylated based on the Intact Masspectrometry results. 
 
The purified Lys-methylated protein was thawed on ice and robotic screening of 
the protein was performed with the commercial 96-well screens. Around 1,000 
commercial conditions were screened at 4°C and RT, respectively. One initial hit was 
generated in the condition of 0.1M CAPS pH10.5 and 40% MPD at 4°C. The following 
optimization was performed through robotic and manual screening, but the crystallization 
couldn’t be optimized.  
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Crystallization of the T4 Lysozyme, EGFP and MBP-(AAA) fused chimeric APC3 
 
Robotic screenings were performed on the T4Lysozyme, EGFP and MBP-(AAA) 
fused chimeric APC3. The proteins were concentrated to 15-20mg/ml (A280 measured) 
after the purification from the affinity chromatography, ion exchange and size exclusion 
chromatography. For each protein, 2,000 of total commercially available conditions were 
screened at 4°C and RT. Only the MBP-(AAA) fusion was found two hits in the 
conditions of 0.1M BTP pH7.5, 20% PEG3350, and 0.2M NaI or KSCN. The MBP-
(AAA) fusion mixed with maltose of a final concentration of 1mM before screening. The 
crystals grew in a shape of small rods (shorter than 0.1mm) or small plates. The 
PEG3350 of a serial of concentrations in the pH 6.5-8.5 was manually screened with the 
0.2M additives of NaI or KSCN, using 96-well homemade blocks. The best 
crystallization buffer turned out to be Tris-Cl pH7.5. More additives screenings were 
performed using the commercial additive screens, and 20 additives out of all positive hits 
were further screened manual (with the original hit condition) to optimize the crystal size. 
The crystals grew into the shape of longer rods (0.1-0.2mm) or rhomboids, and were 
harvested for data collection at Argonne national laboratory (APS), but no crystals 
diffracted.  
 
 
Data collection 
 
The diffraction datasets of high quality were collected at APS, 24-ID-C. The 
dataset was indexed into a space group of C2, and integrated and scaled with HKL2000. 
A fluorescence scan was performed prior to data collection (to another crystal) to 
determine the peak energy/wavelength for Selenium. The dataset was collected at single 
wavelength of λ= 0.9798Å with an exposure time of 0.5 seconds per frame, and a 0.5 
degree oscillation angle for 360 degree collection. The single-wavelength anomalous 
dispersion (SAD) benefits the low anomalous signals to be detected and scaled.  
 
For heavy atoms screening, both the SAD and multiple-wavelength anomalous 
dispersion (MAD) were applied. A few fluorescence scans prior to data collection were 
performed to detect the heavy atom incorporation and optimize the collection strategy. 
The profile of the scans would provide the readouts of the absorption vector f’’, 
dispersion vector f’ and the collection wavelengthes for MAD.  
 
 
Solution and phase determination 
 
The crystallographic structure program phenix.autoso was used to generate the 
solution of the collected dataset and phase the chimeric APC3 structure, through a 
process of automatically determining the Selenium positions, calculating and refining the 
phases, and finally generating an electron density map. The scale file of the input for 
Autosol was from HKL2000 and included the information of a space group (C2), unit cell 
parameters, redundancy (2.2), wavelength (0.9798Å) and the scattering factors (f' -8.0 
and f" 4.5). In order to obtain enough information for the solution calculation, the 
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collected dataset was initially scaled at 2.8Å with a lower Isigma/error of 1. Autosol 
found 70 out of 72 expected Selenium sites and 58 sites have higher than 0.5 occupancy 
scores. In spite of a marginal value of 0.34 of the figure of merit (FOM, the marginal 
range is 0.25 - 0.45), the abundant heavy atoms sites provided a relatively strong phase, 
and leaded to a continuous experimental map with the clear solvent boundaries. The 
initial map has a deviation value (skew) of 0.16 at electron density distribution.   
 
 
Structure refinement 
 
The initial structural model of the chimeric APC3 was built de novo in the 
program Autosol, with poly-Alanines modeled in the initial experimental map, followed 
by the protein sequence docking into the peptide chains. A refinement procedure was 
automatically initiated after docking and generated a refined map with a built-in model. 
The initial model has an Rfree of 0.30. This was followed by repeated cycles of manual 
model building in Coot (70). Then the side chains were placed into the autosol refined 
experimental map, and large errors from the initial models were manually fixed. The 
iterative refinement was performed with phenix.refine (77). The refinement aimed at two 
cycles of xyz coordinates, real-space, global non-crystallographic symmetry (NCS) 
restraints, and automatical Asn/Gln/His errors correction. Those refinement parameters 
are all suitable for diffraction of moderate resolution (lower than 2.5Å). R-free dropped 
from 0.3 to 0.28, which is calculated from randomly selected five percent of all the 
independently measured reflections to prevent the artifact errors introduced by models. 
The refined 2Fo-Fc and Fo-Fc Fourier maps, combining with the ramachandran 
constraints were used for correcting the model errors from the side chains and backbones.  
 
The optimization of x-ray term/stereochemistry and x-ray ADP were incorporated 
into the following 3 cycles of refinement, and 70 water molecules were added/updated to 
the structural model (with the minimal resolution of 3.2Å). The refined model containing 
the newly added water molecules was manually checked after the 3 cycles of refinement.  
Residues of the model and the water molecules that have less than 30% occupancies were 
removed or side-chains truncated before the final refinement cycle. The final cycle of 
refinement of the chimeric APC3 was carried out with water molecules by minimization 
refinement (occupancies) and individual B-factor refinement, resulting in an Rwork and 
Rfree of 22.24% and 25.49%, respectively. All the statistic details of the refined structure 
are available in Table 2-2. 
 
The Ramachandran plot was generated to check the main-chain torsion angles of 
structure model by program Coot (78). The Ramachandran plot has 98% of residues in 
the most favored region and 0.15% in the disallowed region. 
 
 
Co-pulldown assays 
 
The binding capacity tests of the chimeric APC3 to Cdh1 were performed through 
the insect cells Hi-5 in vitro expression. The chimeric APC3s (both long and short 
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version) were fused to a N-terminal His6-MBP tag and cloned to the insect cell 
expression vector pFastBac. Both the full-length APC3 and APC3ΔL constructs were 
tagged with the GST tags. The constructs of Cdh1 and Cdh1WDΔC refer to the full-length 
protein and Cdh1 residues 162-462, respectively. Both these constructs were tagged with 
a N-terminal 3Myc-His6 and the Myc tag refers to a peptide sequence of N-
EQKLISEEDL-C. Hsl130 refers to yeast Hsl1 residues 770-790 fused to residues 818-
842, and together this sequence reconstitutes the substrate KEN and D-box motifs, which 
are recognized by the APC co-receptors.  Hsl130 was tagged with a N-terminal twin strep 
tag (two copies), and each strep tag consists of residues N-WSHPQFEK-C. All the 
sequences of these constructs were verified by DNA sequencing.  
 
The pFastBac constructs were then transformed into the competent cells of E. coli 
EMBacY strain (79), which generated the recombinant Bacmids (a baculovirus shuttle 
vector) to carry the genes for co-pulldown experiments. The transformed competent cells 
were cultured in 1ml Super Optimal Broth (SOC) media at 37°C for 6hrs before they 
were plated onto LB-agar plates containing 100µg/ml ampicillin, 50μg/ml kanamycin, 
10μg/ml tetracycline and 7μg/ml gentamycin. All the LB-agar plates were supplemented 
with 100μg/ml Xgal and 40μg/ml IPTG in advance to enable the lacZ blue-white 
selection to identify the white colonies being incorporated with the gene of interest. The 
white colonies were re-streaked onto fresh plates with the same supplements and 
incubated at 37°C for another day. The colony-PCR valued positive colonies were 
amplified overnight for preparing Bacmid DNA. The over-night culture medium kept the 
same antibiotics as the LB-agar plates.  
 
After cells were harvested from the over-night cultures, the cell pellets were 
resuspended in 300μl of Qiagen buffer P1, lysed by addition of 300μl of Qiagen buffer 
P2 at room temperature for five minutes and recovered on ice for ten minutes by 
incubating with another additional 300μl of Qiagen buffer P3. The precipitation was 
pelleted at room temperature by centrifugation at 13,000rpm for 10 minutes. The cleared 
lysate 700μl was added to 800μl of ice cold isopropanol and incubated for 5 minutes on 
dry ice. The precipitated Bacmid DNA was pelleted at room temperature by 
centrifugation at 13,000rpm for 10 minutes and the pelleted DNA was washed with 70% 
(v/v) Ethanol. The clean Bacmid DNA was resuspended in 50μl of sterile elution buffer 
(Qiagen) inside a laminar flow hood (sterile conditions). 
 
Insect cell Sf9 was used to produce and amplify the baculovirus of infection. 
Bacmid DNA 1-2µg were diluted into 100µl serum-free media and then mixed with 10µl 
of FuGene HD transfection reagent. The transfection mix was then incubated at 27°C for 
30 minutes before being diluted by 1ml serum-free medium. The diluted mix was then 
added into a 6-well plate that is freshly coated with 2×106 healthy Sf9 cells and was 
incubated with Sf9 cells at at 27°C for 6 hours. After transfection, another 2ml of serum-
free medium was added back into the Sf9 cells for continuous incubation for 4-5 days at 
27°C. The baculovirus were harvested when infected Sf9 cells began to produce green 
fluorescence signal (under UV excitation). The harvested virus was the 1st generation and 
it needed to be amplified for another two rounds before infection. The virus was 
amplified in 25mm cell culture dishes with each dish freshly coated by ~20×106 healthy 
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Sf9 cells. Each amplification mix was made by mixing 500µl of 1st generation virus with 
5ml of serum-free medium and then the mix was added into 25mm dishes before 
incubation at 27°C for 2 hours. After 2 hours, another 15ml of serum-free medium was 
added into each dish for 3-day incubation at 27°C before 2nd generation of baculovirus 
was harvested. The 3rd generation of baculovirus was prepared with the same procedure.  
 
Co-infections were performed on Hi-5 insect cells at a density of 10-20×106 
cells/ml by adding the 3rd generation of baculovirus. The infected cells were cultured at 
27°C for 2 hours at a speed of 120 revolutions per min (rpm) and then followed by 
incubation at 20°C for 2 days. The co-infection was set up in 200ml for each co-
pulldown, and the baculorvirus used for infection was kept at the ratio of 1:100 (the 
volume of viruses: infection). The infected Hi-5 cells were harvested and cell pellets were 
resuspended in a buffer of 50mM Tris-HCl pH7.6, 0.2M NaCl and 5mM DTT (wash 
buffer), supplemented with 10ug/ml Aprotinin, 5ug/ml Leupeptin, one tablet of the 
protease inhibitor per 50ml of the wash buffer (Sigma) and 2.5 mM PMSF, and lysed by 
sonication on ice. The lysates were spun at 4°C twice, at 15,000rpm for 20 minutes and 
then the supernant were incubated with strep-tactin sepharose (IBA) on a rotary shaker at 
4°C for 1 hour. Half-milliliter slurry of the strep-tactin beads (0.25ml) was used for each 
co-pulldown. The protein-bound strep beads were then washed twice with two bead-
volume of the wash buffer before loading on the column, followed by a column wash 
with 20 bead-volumes of the wash buffer. The proteins of each co-pulldown were 
eventually removed from the beads with an elution buffer of 50mM Tris-HCl pH7.6, 
0.2M NaCl, 5mM DTT and 2.5mM dethiobiotin, and each elution was examined by SDS-
PAGE. 
 
 
The models of the APC subunits docking in the APC EM maps 
 
Human APC10 model (PDB code: 1JHJ) was used for docking in APC10 density 
with the N-terminal 9 residues removed from the atomic coordinates. The N-terminal 
loop (9 residues) has no matching density in both EM maps, EM2226 and EM 2354. The 
density of the Cdh1 propeller domain was docked with S. cerevisiae Cdh1 molecular 
model (PDB code: 4BH6), with the coordinates of the Cdh1 inhibitor Acm1 removed. 
The coordinates of the inhibitor KEN box and D-box were kept with the Cdh1 docking 
model. The WD40 propeller domains of the human and yeast Cdh1 had a high sequence 
identity of 49%. All the models for the EM map docking are originally predicted by I-
tasser server (73). The TPR7-14 of the human APC3 was modeled based on the atomic 
model of human Acetyl-Glucosaminyl Transferase (PDB code: 1w3b) with an overall 
sequence identity of 17%. The TPR1-6 of APC3 was modeled based on S. pombe APC6 
molecular model (PDB code: 2xpi) with a 15% sequence identity. The other TPR 
subunits, APC7, APC6 and APC8 are all modeled from S. pombe APC6 structure, with 
the sequence identities of 15%, 36% and 18%, respectively. The crystallographic models 
of human C-terminal APC6 and N-terminal APC7 were incorporated into the 
corresponding docking models, respectively (PDB code: 3HYM, 3FFL). 
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All the model docking were performed through the software Chimera (80). The 
model editing and superimposition were done through COOT (81) and Pymol (82). Each 
model was manually docked into the corresponding density of the APC EM maps with a 
potential orientation, followed by the optimized local fitting through Chimera “fit in 
map” function, which adjusted the orientations of the filled models based on the 
calculated correlation coefficients. The docking was repeated through multiple rounds of 
iteration process including model re-editing and repeated docking till the most reasonable 
and/or the best fitting was achieved. The N-terminal and C-terminal coordinates of all the 
TPR subunits were docked in separately. After docking, each EM-derived structure was 
calculated for the correlation related to the EM maps. 
 
The editing of the docking models was also guided from the model 
superimpositions. The superimposition of each model was adjusted with reference to the 
sequence comparisons of the APC subunit orthologs, and the 2nd structures corresponding 
to the same TPR motifs were manually aligned together in Coot. 
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CHAPTER 3. INTERACTION STUDY OF THE CO-ACTIVATORS WITH APC3, 
APC8 AND THE APC PLATFORM 
 
 
Introduction 
 
During the cell cycle, APC co-activators Cdh1 and Cdc20 are recruited to the 
complex through their C-terminal highly conserved IR-tails (33, 34, 36, 37). Whereas on 
the APC scaffold, the homo-dimeric TPR subunit APC3 is responsible for the co-
activator recruitment. Cdh1 and APC10 also function as substrate receptors. APC 
substrates are recruited between Cdh1 and APC10 in a D-box (destruction motif) 
dependent manner. D-box is a common sequence within substrates that allows the APC to 
identify the substrates. An APC EM study revealed that Cdh1 and APC10 are connected 
through the substrate D-box once the substrate is bound (31, 32), although APC10 itself 
has weak affinity to substrates. Moreover, the ratio of co-activators and APC10 is 
maintained at 1:1 in an active APC complex.  
 
Besides IR-tail mediated interaction, Cdh1 and Cdc20 were also found to have 
multiple interactions with the APC, and together these interactions generate high-affinity 
binding of the activator to the APC core. Cdh1 interacts with another TPR subunit, APC8 
at C-terminal unknown sites (34) and also with APC2,  since the removal of APC2 leads 
to reduced Cdh1 association (18). Cdh1 substrate-recruitment domain, the WD40 
propeller, also shows some weak interactions with APC3 (33). It is likely that the high-
affinity interactions keep activators bound during multiple substrate-binding of 
ubiquitination events (34).  
 
The TPR subunits APC3 and APC8 both have 14 TPR motifs, with N-terminal 
TPR1-4 mediating TPR subunit dimerization. The study of APC recruiting co-activators 
will help understand the APC ubiquitination mechanism and APC activity regulation 
during the cell cycles.  
 
 
Results and Discussion 
 
 
Cdh1 binds to APC3 mainly through its C-terminal IR-tail peptide 
 
In order to understand the recruitment mechanism of activators to APC, I 
reconstituted the interaction in vitro between the activators and APC3 or APC8. It was 
shown by previous lab members that most APC subunits could not be expressed in E. coli 
strains, and thus an insect cell expression system was chosen to perform experiments in 
this chapter. One approach used to investigate their interaction is co-pulldown assays. 
Principally, I co-expressed the various proteins fused with GST, Strep, His-MBP affinity 
tags in insect cells and detected their interaction through affinity purification, followed by 
examination of the purified products through SDS-PAGE (Figure 3-1a). 
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Figure 3-1. Human Cdh1 binds to APC3 and APC8 in vitro. 
 
(a) Schematic representation of co-purification/co-pulldown procedure.  
(b) Left:  SDS-PAGE co-pulldown result of the GST-Cdh1 and APC3 (left), Cdh1 and 
GST-APC8 (right) from insect cell co-infections. All the bands labeled were identified by 
mass spectrometry. Molecular weight standards are labeled on the left side of the gel. 
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In vitro purified Cdc20 and APC10 behave poorly; therefore, Cdh1 was used for 
all the interaction studies in this chapter. Previously, the interactions of Cdh1 with APC3 
and APC8 were tested by co-pulldown from Hi-5 insect cells. APC3 and APC8 could be 
co-purified with Cdh1 (Figure 3-1). GST (Glutathione S-Transferases) affinity tag was 
used for this experiment. Although the stoichiometry between APC3, APC8 and Cdh1 are 
not 1:1 in this initial experiment, the results demonstrated that the association between 
APC3 or APC8 and Cdh1 were reconstituted in vitro. Cdh1 expression was previously 
shown to be very impure, characterized by a lot of contaminants associated during 
purification (Figure 3-1b, left). Compared to most other subunits of the APC, APC8 
expressed relatively well by itself. The unequal stoichiometry is probably because the 
GST-tagged proteins expressed better than the un-tagged binding partners (Figure 3-1b, 
right).  
 
The co-pulldown experiments of Cdh1 with APC3 and APC8 were optimized 
through two strategies. One is to improve Cdh1 behavior by co-purification with yeast 
APC substrate peptide Hsl130 and the other strategy is to perform a co-pulldown on the 
twin-Strep tag that was fused to the Hsl130 C-terminus. Hsl1 is a yeast APC substrate and 
it associates with Cdh1through its D-box (destruction box) and KEN box motif (83, 84).  
The D-box and KEN-box are the sequence elements inside most APC substrates that bind 
to the Cdh1 WD40 propeller domain. The Cdh1 WD40 domain functions as a D-box and 
KEN box receptor (33). Hsl130 is a shorter version of Hsl1 that only contains its D-box 
and KEN-box. The substrate peptide stabilizes Cdh1, making it behave better. The co-
purified Cdh1-Hsl130 has less associated contaminants and adopts more homogenous 
conformations based on Cdh1 purification experiments from previous lab members. 
 
In order to explore the ability of each Cdh1 domain to interact with APC3, the 
Cdh1 protein sequence was analyzed and serial deletions of Cdh1 were constructed for 
co-pulldown experiments (Figure 3-2a). The activator Cdh1 has similar structure 
domains/motifs: C-box, WD40 propeller and C-terminal IR tail peptides as Cdc20. N-
terminal Cdh1 was serially truncated towards the WD40 domain in units of 20 amino 
acids, and the C-terminal IR tail peptide was also deleted. The N-terminal 160 residues of 
Cdh1 without the WD40 domain are not able to bind substrate Hsl130 by themselves 
(Figure 3-2b). Except the Cdh1N160 pulldown, which was performed on the twin-strep tag 
of APC16, all other co-pulldown experiments were performed on the twin-strep tags of 
the Hsl130. 
 
To improve the behavior of human APC3, APC3ΔL substituted for the full-length 
protein for the experiment. APC3 is a highly hydrophobic protein due to its high α-helix 
content. The full-length protein aggregates in the absence of stabilizing partners. APC3 
has a large disordered loop between TPR 4 and 5 and deletion of that region — APC3ΔL 
effectively limits the aggregation. The disordered loop was discovered as a highly 
phosphorylated region (85) and it mediates the APC3 interaction with APC7. APC16 was 
recently identified as a small subunit of the APC to stabilize APC3 association with 
APC7 (86).  APC16 binds to both APC3 and APC3ΔL, and the disordered loop of APC3 
has no contribution towards binding with APC16 (Figure 3-2b). 
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Figure 3-2. Map human Cdh1 domains required to interact with APC3. 
 
(a) Illustration of the domain mapping strategy for APC3ΔL, Cdh1 co-pulldown 
experiments. APC3 is represented in a green parallelogram, APC16 in a red sphere and 
Cdh1 in a blue octagon, with their construct schematics listed below. A GST affinity tag 
was fused to the APC3ΔL N-terminus and a Strep tag was fused to the Hsl130 C-terminus. 
Each co-expression had the protein components of APC3ΔL, APC16, Cdh1(full length or 
truncated), Hsl130. Strep tagged APC16 was used for the APC3∆L co-expression with 
Cdh1N160 and the non-tag APC16 was used in the other co-expressions. Human Cdh1 
constructs included C-terminal IR peptide deletion (∆C), a serial of N-terminal truncation 
(∆20-140, residues number) and N-terminal fragment 1-160. WD40 domain is the Cdh1 
substrate-binding region. Insect cell Hi-5 strain was used for co-expression and the 
experiment was performed on a Strep tag. 
(b) SDS-PAGE of purified product from APC3ΔL, Cdh1 co-pulldown experiments. 
Protein loading for each lane was normalized to Cdh1. Molecular weight standards are 
labeled on the left side of the gel, and the protein bands on the gel were labeled with their 
names and their schematic illustrations. 
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Cdh1 deletions were well expressed in insect cells (Hi-5 strain) and all the 
deletions were pulled down by Hsl130-Strep except Cdh1N160. Compared to the deletion 
of Cdh1 IR tail peptide, the N-terminal deletions mildly affect Cdh1 interaction with 
APC3ΔL (Figure 3-2b). The amount of APC3ΔL co-purified with N-terminal deletions 
dropped down to half the amount of APC3ΔL co-pull down with full-length Cdh1. 
Without the C-terminal IR tail, APC3ΔL could barely interact with Cdh1. This result 
matches literature reports that the Cdh1 IR tail is critical for mediating APC3 interaction 
(37). There was no significant difference among the co-pulldowns from Cdh1 N-terminal 
deletions, which could be because co-pulldown assays are not sensitive enough to 
differentiate weak interactions.  
 
To compensate for the limitation of co-pulldown assays and also to measure the 
kinetics of APC3 and Cdh1 interaction, other approaches including ITC (Isothermal 
Titration Calibration), SPR (Surface Plasmon Resonance) and native gel shift assay were 
applied.  APC3, APC3ΔL and Cdh1 only behave well under the experimental conditions 
of native gel shift assays (4°C), but not at room temperature. The interaction between 
APC3 and Cdh1 did not produce a significant thermal change to be measured through 
ITC. The native gel shift assay is able to detect nM binding affinities of protein-protein 
interactions under native conditions through a polyacrylamide gel. It turned out to be the 
approach that produced detectable results in this study. The interacting protein pairs have 
a different mobility on PAGE compared to the non-binding proteins in the control.  
 
Except Cdh1N160, all other Cdh1 deletions used for native gel shift assay were co-
purified with Hsl130 from double affinity tag chromatography, followed by gel filtration. 
APC3ΔL-APC16 is purified and stored as a 1:1 stoichiometric protein complex and this 
complex forms a band on the native gel at pH 8.2, 4°C (Figure 3-3b). All the Cdh1-
Hsl130 complexes and Cdh1N160 were unable to electrophorese into native gels because of 
their basic pI value. Therefore, the gel shift experiment was designed to detect the band 
shift of the APC3ΔL-APC16 complex.  
 
No APC3ΔL-APC16 band was detected in the presence of Cdh1FL-Hsl130, 
indicating that all the loaded APC3ΔL-APC16 (in vitro purified complex) was bound to 
Cdh1. When Cdh1Δ140-Hsl130 interacts with APC3, APC3ΔL-APC16 runs as a smear on 
the native gel instead of a band or disappearance. It might be because the conformation of 
APC3ΔL-Cdh1 complex is different when the Cdh1 N-terminal 160 residues are missing.  
Cdh1’s N-terminal 140 residues by themselves don't shift the APC3ΔL-APC16 band on 
the gel. It seems that N-terminal Cdh1 is not necessary to mediate the interaction with 
APC3 although the co-pulldown experiment showed less APC3ΔL bound to the N-
terminal deletion.  
 
Cdh1ΔC-Hsl130 also demonstrates some weak interactions with APC3 in this 
approach, which could be contributed from the WD40 propeller domains.  The WD40 
propeller domains of yeast Cdh1 were observed to have multi-site weak cross-linking 
interactions with APC3, and C box also has a one site weak-interaction with APC3 (33).  
 
  
 79 
 
 
 
 
Figure 3-3. Identify Cdh1 binding domains to APC3. 
 
(a) Illustration of experimental procedure for the native gel shift assay. APC3 is 
represented in a green parallelogram, APC16 in a red sphere and Cdh1 in a blue octagon, 
with their construct schematics listed below. Purified proteins or protein complexes were 
used for the experiment. The protein complexes APC3ΔL-APC16 and Cdh1(full length or 
truncated)- Hsl130-Strep were purified separately from insect cell Hi-5 expression. Cdh1N160 
was purified by itself without Hsl130-Strep. Beside a full-length construct used for this 
asaay, human Cdh1 constructs also included C-terminal IR peptide deletion (∆C), a N-
terminal 140 residue truncation (∆140) and N-terminal fragment 1-160. WD40 domain is 
the Cdh1 substrate-binding region.  
(b) Native gel shift to examine the interaction between APC3ΔL and Cdh1. The control 
lanes are marked with an orange line at the bottom of the gel and the experimental lanes 
are marked with a green line. APC3ΔL-APC16 was mixed with Cdh1-Hsl130-Strep (full 
length or truncated) at a 1:10 molar ratio and incubated on ice for 20 minutes before 
loading. 21µM APC3ΔL-APC16 was used as a control and for each mixture. The protein 
complex band on the gel was labeled with its name and a schematic illustration. 
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Study of the IR-tail APC3 interactions via an IR-tail mimicked compound 
 
The compound TAME is designed to inhibit APC activity by mimicing the IR tail 
structure of activators Cdh1, Cdc20 and co-receptor APC10, which all interact with 
APC3 through their C-terminal highly conserved IR tail. TAME disrupts the activator 
association with APC and inhibits the APC activity (40, 51). TAME uses a tosyl group to 
mimic Ile, and it also has a methyl ester group on the Arg carboxyl.  
 
The interaction between TAME and APC3 protein complexes were detected by 
WaterLOGSY (water-ligand observed via gradient spectroscopy).  The experiments were 
performed at room temperature after proteins were mixed with TAME in pH 7.0 
phosphate-buffered saline (PBS) with 10% D2O. In WaterLOGSY experiments, the 
interacting ligands receive magnetization transferred from bulk water via the water 
molecules buried in binding pockets and labile protein protons, through the mechanism of 
NOEs (Nuclear Overhauser Effect) and chemical exchange. The experiments are 
designed to achieve efficient selective water excitation, which tends to detect the signal 
from interacting ligands by inverting the water signal (71, 87). The intensity of non-
binding and tight binding ligands are characterized as negative amplitudes and those of 
weak interacting ligands are positive. For the tight binding ligands, the negative intensity 
results from either less water molecules inside unfilled binding pockets or a slower 
proton-exchange rate. 
 
During any WaterLOGSY screening, the solvent signals (~5ppm) were 
suppressed to limit the artifacts in the spectrum. The peaks in this experiment were 
distributed from 1.5ppm to 7.5ppm. The downward peaks from the compound reference 
spectrum are signals from free ligands — non-binding TAME. The corresponding peaks 
of waterLOGSY spectrum inverted (upwards) in the presence of APC3 protein complex 
imply the interactions between APC3 and TAME. TAME specifically binds to APC3 
complexes but not to Cdh1-Hsl130, and each peak was assigned to a proton of TAME 
according to their ppm value (Figure 3-4a).  
 
WaterLOGSY is a sensitive approach to detect relatively weak interaction 
between proteins and ligands. Signals indicating weak interaction have positive 
amplitude in the spectrum. Peaks one to four and peak six of the experimental spectrums 
revealed weak interaction between TAME and APC3, which were not affected by APC3 
mutant and APC3ΔL (disorder loop deletion) (Figure 3-4b). Four of the interactions are 
contributed by tosyl protons and one is from methyl protons (Figure 3-4a).  Meanwhile, 
peak five and seven pointed downwards in the spectrum of wild type APC3 with TAME, 
and they inverted upwards in the spectrum of APC3ΔL and APC3mut. Peak five and 
seven were the proton signal of the Arg group, and therefore the inversion indicated the 
Arg interaction with APC3mut or APC3ΔL is weaker than with wild type APC3.  Peak 
three was detected in the spectrum of APC3 complexes with TAME but not in the 
compound reference spectrum. It is probably because the signal from proton three is very 
subtle if TAME is the free ligand in solution. Combining all the peaks in the three 
experimental spectrums, I can see that TAME interacts with APC3 with its tosyl group, 
Arg group and methyl easter, with the Arg group binding relatively tighter than the other 
two.   
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Figure 3-4. Compound TAME mimics the IR tail interactions with APC3. 
 
(a) Structure illustration of compound TAME and IR tail. Groups are illustrated in green 
color.  
(b) One-dimensional WaterLOGSY spectra record of APC3 interaction with TAME. The 
five spectra from the top are the reference spectrum of three APC3 complexes (2µM 
each), 2µM Cdh1-Hsl130-Strep complex and 0.2mM compound TAME. Another four 
spectra from the bottom are the corresponding 2µM protein complexes in the presence of 
0.2mM TAME. The peaks labeled out by orange and blue arrows are the signals of the 
protons in TAME, with the same set of numbers as in (a). The peaks labeled out with 
blue arrows indicate stronger interactions than those with orange arrows. The spectra 
were acquired with 10920 scans and protein signals were destroyed with the design of 
WaterLOGSY pulse sequence.  
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The mutated residues of APC3 are the residues that are conserved in the APC3 
binding groove (Figure 2-10), which have been reported to reduce the association of 
Cdh1 with APC (34). The NMR WaterLOGSY results showed N581A/L612A decrease 
the affinity of the Arg (of the IR tail) to APC3 but do not completely disrupt the 
interaction.  Given ten conserved residues of the binding groove surface potentially 
mediate IR tail recruitment, the mutation of two residues is probably not sufficient to 
eliminate the interaction. APC3ΔL has no mutation in the binding groove but still has a 
similar defect as the APC3 mutants.  The wild type APC3 of the APC3-APC7-APC16 
complex appears to have better overall structure to stabilize the interactions with the IR 
tails. 
 
 
APC8 interacts with N-terminal Cdh1 
 
 APC8 has similar aggregation behavior as APC3 if it is purified by itself. The 
strategy to solve the aggregation problem is to co-purify it with APC13 and APC6-Cdc26 
complex. APC6 is an APC TPR subunit and it requires Cdc26 to fold into the correct 
conformation (26, 27). APC6 associates with APC8 tightly in vitro. APC13 is a small 
subunit that promotes the stable association of APC6 and APC3 to the APC complex 
(25), originally identified in yeast. Human APC13 also binds to APC8 in vitro but could 
not rescue APC8 alone from aggregation. Therefore, APC6-Cdc26 and APC13 are both 
used to stabilize APC8.  
 
Compared to the interaction between APC3 and Cdh1 in their co-pulldown 
experiment, APC8 turned out to be a much weaker interacting partner for full-length 
Cdh1 (Figure 3-5).  The Cdh1 N-terminal deletions appeared defective in pulling down 
APC8, and the difference among all the deletions also became indistinguishable. 
Nonetheless, the N-terminal Cdh1 showed a greater propensity towards binding APC8 
over APC3.  
 
To identify the Cdh1 binding domains to APC8 and compare the results to the 
interactions between Cdh1 and APC3, the same set of Cdh1 deletions were used for 
native gel shift assays.  It appears that Cdh1 is able to bind to the APC8-APC6 complex 
only when the N-terminal 140 residues are present, and the interaction disappears when 
the N-terminal 140 residues were deleted (Figure 3-6). However, those N-terminal 
residues alone could not interact with APC8 if they are expressed/purified by themselves 
(without the WD40 domain).  
 
The APC8-APC6-Cdc26-APC13 complex for native gel shift assay is prepared 
through affinity chromatography on the GST affinity tag fused to APC8, followed by ion 
exchange chromatography and gel filtration. These gel shift results are reproducible.   
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Figure 3-5. Map human Cdh1 domains required to interact with APC8. 
 
(a) Schematic illustration of the domain mapping strategy for APC8, Cdh1 co-pulldown 
experiments. APC8 and APC6 are represented in a pink and a yellow parallelogram, 
respectively, with APC13 and Cdc26 separately shown in a cyan and a light-blue sphere. 
Cdh1 is demonstrated with a blue octagon, and the schematics of all the constructs used 
for the co-pulldown are listed below. Human Cdh1 constructs included C-terminal IR 
peptide deletion (∆C), a serial of N-terminal truncation (∆20-140, residues number) and 
N-terminal fragment 1-160. WD40 domain is the Cdh1 substrate-binding region. A GST 
affinity tag was fused to the APC8 N-terminus and a Strep tag was fused to the Hsl130 C-
terminus. APC8, APC6, APC13, Cdc26, Cdh1(full length or truncated), and Hsl130-Strep were all 
co-expressed in insect cell Hi-5 strain. The experiments were performed on a Strep tag 
except the one with Cdh1N160, which was performed on a GST tag. 
(b) SDS-PAGE of purified product from APC8, Cdh1 co-pulldown experiments. Protein 
loading for each pulldown was normalized to Cdh1. Molecular weight standards are 
labeled on the left side of the gel, and the protein bands on the gel were labeled with their 
names and their schematic illustrations. 
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Figure 3-6. Identify Cdh1 binding domains to APC8. 
 
(a) Schematic illustration of constructs used for APC8, Cdh1 native gel shift experiments. 
Purified proteins were used for the experiment. APC8 and APC6 are represented in a 
pink and a yellow parallelogram, respectively, with APC13 and Cdc26 separately shown 
in a cyan and a light-blue sphere. Cdh1 is demonstrated with a blue octagon, and the 
schematics of the constructs used for the assay are listed below. Human Cdh1 constructs 
included C-terminal IR peptide deletion (∆C), a N-terminal truncation of 140 residues 
(∆140) and N-terminal fragment 1-160. WD40 domain is the Cdh1 substrate-binding 
region. The protein complexes APC8-APC6-APC13-Cdc26 and Cdh1(full length or truncated)-
Hsl130-Strep were purified separately by co-expression in insect cell Hi-5 strain. Cdh1N160 
was purified by itself without Hsl130-Strep.  
(b) Native gel shift to examine the interaction between Cdh1 and APC8 with APC8 as 
part of the APC8-APC6-APC13-Cdc26 complex. The control lanes are marked with an 
orange line at the bottom of the gel and the experimental lanes are marked with a green 
line. The APC8 complex and Cdh1(full length or truncated)-Hsl130-Strep  were mixed on ice for 
20 minutes before loading. 18µM APC8-APC6-APC13-Cdc26 was used in both the 
control and in each mixture. The molar ratio of Cdh1(full length or truncated) to APC8 complex 
is 10:1. The protein complex band on the gel was labeled with its name and a schematic 
illustration. 
  
 85 
The interaction of N-terminal Cdh1 with the APC platform  
 
N-terminal Cdh1 is predicted to fold into α-helices (by Psipred, Figure A-6) (68) 
and the corresponding densities are identified towards the inside of the APC. But the 
molecular envelopes of all the published EM maps are not clear/detailed enough for the 
N-terminal secondary structure assignment. The APC quaternary structure displays both 
the APC8 and APC1 repeats are connected with N-terminal Cdh1 by strong densities 
(Figure 3-7a). The green spheres mark the corresponding mutation in APC8 (N339A) 
that was reported to reduce yeast Cdh1 association to APC in vivo (34). The APC 
topological structure displays the APC8 mutation is in close proximity to N-terminal 
Cdh1 density, suggesting it mediates interactions between these two subunits. The 
disruption to the interaction of APC8 with Cdh1 begins with Cdh1 N-terminal 20 
residues deletion, and N-terminal 20 residues are predicted to form two α-helices (Figure 
3-5b, Figure A-6). It implies that the N-terminal 20 residues of Cdh1 contact APC8. 
 
To test the interaction between Cdh1 and other APC subunits (mainly platform 
subunits), more native gel assays were performed (Figure 3-7b). The recombinant APC 
platform, which includes all the non-TPR subunits, appeared as a clearly visible band on 
a native gel with or without APC8-APC13. The clear bands from the native gel indicate 
that the majority of the complexes have a rigid and homogenous conformation. The same 
set of Cdh1 deletions from APC8 and APC3 binding test were used for the assay. 
 
The full-length and C-terminal peptide deleted Cdh1 both bind to APC8/APC13 
+/− platform (Figure 3-7b). The interaction disappears without N-terminal Cdh1 (before 
WD40 domain). The gel shift patterns are similar to the ones of the APC8 TPR complex 
interacting with Cdh1 (Figure 3-6b). Cdh1(fl or Δ140) attached to the APC8-APC13-
platform forms a shifted band on the gel, whereas the majority of the Cdh1(fl or Δ140) -
platform disappears or becomes a smear. This may mean the Cdh1(fl or Δ140) -platform has 
a more flexible conformation without APC8-APC13. The interaction between APC8 and 
Cdh1 might stabilize the association of Cdh1 with other platform subunits. 
 
Same as the native gel shift results of Cdh1 with APC8 and APC3, the 
recombinant N-terminal fragment of Cdh1 did not show any interaction with either 
platform complex. There could be many explanations for this. The Cdh1 N-terminal 
fragment seems to have flexible folding, and half of the fragment is predicted to be a 
disordered loop (Figure A-6). The EM-derived N-terminal helices only cover 60% of the 
fragment sequence and other residues of the disordered loops could not be identified 
through the current EM maps. One possibility is that the Cdh1 N-terminal fragment will 
fold accordingly once it comes in contact with the APC platform subunits. 
 
 
Implication of Cdh1 N-terminal interactions 
 
The amounts of co-activators bound to APC are rate-limiting for ubiquitination 
reactions (88), and therefore it is important and interesting to understand how co-
activator association supports APC ubiquitination activity. Multiple previous studies   
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Figure 3-7. N-terminal Cdh1 interacts with the APC platform. 
 
(a) Human APC architecture demonstrated by EM-derived structures and APC4-
APC5 EM map (yellow mesh, EMD 1843) (89) docked into the corresponding 
densities on the APC EM map (EMD 2354) (23). The locations of APC2 and APC11 
are annotated as a yellow circle and the APC platform is outlined with a red dash line. 
The model of the N-terminal Cdh1 includes a bunch of α-helices extending towards 
the inside of the APC (left). The green spheres indicate the corresponding APC8 
residue that decreased Cdh1 association with the yeast APC (32). The blue circle 
mark the localization of the density contributed by the N-terminal Cdh1, with two 
close views demonstrating the interactions of N-terminal Cdh1 with APC8 and APC1 
PC repeats.  
(b) Native gel shift assays to identify the Cdh1 domains required for APC8 +/− 
platform interaction (top, middle panels), with GST-ubiquitin as an interaction control 
(bottom panel). The control lanes in each gel are marked with an orange line at the 
bottom of the gel and the experiment lanes are marked with a green line. APC8 +/− 
platform or GST-ubiquitin were mixed with Cdh1(full length or truncated)-Hsl130-Strep, 
respectively, on ice for 20 minutes before loading. 5µM APC8-platform, 3.8µM 
platform and 37µM GST-ubiquitin were used as controls and for each mix. The molar 
ratio of Cdh1 (full length or truncated) to APC8 +/− platform or GST-ubiquitin is 
10:1. The protein complex band on the gel was labeled with its name and a schematic 
illustration. 
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Figure 3-7. (Continued). 
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showed that the attachment of Cdh1 to APC is stabilized by multiple interactions, which 
likely supports that Cdh1 binds when ubiquitinated substrates are released from the APC 
(18, 34). 
 
The interactions between APC3 and the IR-tail peptides of the co-activators or 
APC10 have been well characterized by biochemical and structural approaches, although 
their atomic details remain unknown. In contrast, the Cdh1 association to other APC 
subunits is still not well understood. In addition to the reported interactions of Cdh1 with 
APC being confirmed in this chapter (18, 33, 34, 37), the EM-derived structures are also 
incorporated to shed light on revealing the mechanism. Potentially, the N-terminal Cdh1 
helices interact with APC8, APC1 PC repeats and APC4-APC5 
 
 Given that the disordered regions of N-terminal Cdh1 couldn’t be identified 
through the EM map, biochemical assays will be required to determine the binding details 
between the Cdh1 N-terminal regions and the platform subunits. To characterize the role 
of the N-terminus of Cdh1 in the multi-interaction, more thorough Cdh1 N-terminal 
deletions/mutations would be required to test binding with the APC platform, 
recombinant APC1-APC4-APC5, and in vitro purified single platform subunits. Since 
APC2-APC11 couldn’t form a visible band in a native gel, this approach is not applicable 
for the catalytic subunits. Meanwhile, the crystallization of the APC platform with Cdh1 
would be an alternative approach to reveal the details of their interaction. 
 
Human Cdh1 is subject to phosphorylation in vivo by Cdks (Cyclin-dependent 
kinases), and the Cdk-dependent phosphorylation sites are responsible for blocking the 
APC interaction with Cdh1. APCCdc20 inhibits the recruitment of Cdh1 to the APC by 
phosphorylating Cdh1 until the latter stages of mitosis (88, 90). The majority of the 
phosphorylation sites are at the N-terminal fragment (before the conserved WD40 
domain) (85, 88), and therefore, phosphorylation interrupts Cdh1 binding to APC.  In 
vitro, phosphorylated Cdh1 binds to or activates the APC less efficiently when compared 
to non-phosphorylated Cdh1, whereas non-phosphorylatable Cdh1 mutants constitutively 
activate APC in vitro and in vivo (90). Combining the effects from Cdh1 phosphorylation 
with the data on Cdh1’s multi interactions with the APC may further elucidate the 
mechanism of how Cdh1 association regulate APC activity.  
 
 
Materials and Methods 
 
 
Constructs and insect cell infection 
 
Protein expression constructs were made by standard PCR/ligation procedures, 
and sequences were verified by automated sequencing procedures. The APC3 deletion 
and mutation were designed in reference to the human APC3 830 a.a sequence isoform 
(uniprot code: P30260). The disordered region of residues 182-453 were deleted for 
APC3ΔL, and APC3mut refers to APC3 with Asn581 and L612 both mutated into Ala. 
The APC16 construct includes the full-length protein sequence of APC16 (uniprot code: 
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Q96DE5), and APC1674 refers to residues 74-110.  The constructs of APC8, APC6, 
Cdc26 and APC13 also used the full-length protein sequence (uniprot code: Q9UJX2, 
Q13042, Q8NHZ8 and Q9BS18). Human APC8 refers to the isoform with 597a.a. For 
the chimeric APC3, there is a long version and a short one. The long version fused the N-
terminal residues 1-241 of E. cuniculi APC3 to Human APC3 residues 539-830. The 
short one used the E. cuniculi residues175-241 to fuse to Human APC3 residues 539-830. 
Hsl130 was made by cloning yeast Hsl1 residues 770-790, which includes a KEN box, 
and residues 818-842, which includes a high affinity D-box, into the substrate peptide. 
Human Cdh1 has 496a.a. (uniprot code: Q9UM11). Cdh1ΔC refers to the last 17 residues 
deleted from the C-terminus, and Cdh1Δ20-140 means the corresponding number of 
residues deleted from N-terminal Cdh1.  The Cdh1 WD40 propeller domain includes 
residues162-479, and the C box refers to residues 45-52.   
 
All the constructs described in this chapter were expressed using the Bac-to-Bac 
baculovirus expression system (Invitrogen). The sequences-verified pFastBac constructs 
were transformed into E. coli DH10B or E. coli EMBacY competent cells, which contain 
a baculovirus shuttle vector — a bacmid to generate the recombinant bacmids carrying 
the genes of interest (79). Transformed cells were incubated at 37°C for 4hrs to allow the 
pFastBac expression cassette to be incorporated into bacmids by the Tn7 transposon.  The 
culture was plated onto LB-Agar afterwards that contained 100µg/ml ampicillin, 50μg/ml 
kanamycin, 10μg/ml tetracycline, 7μg/ml gentamycin, with 100μg/ml Xgal and 40μg/ml 
IPTG to enable lacZ blue-white selection of the clones containing the gene of interest 
(white colonies). The plates were incubated at 37°C for 1.5-2 days and then the white 
colonies were re-streaked and re-evaluated by colony PCR. Positive clones were 
amplified in an over-night LB medium containing 100µg/ml ampicillin, 50μg/ml 
kanamycin, 7μg/ml gentamycin and 10μg/ml tetracycline at 37°C. 
 
 The recombinant pFastbac plasmids were purified via the Qiagen miniprep 
protocol, while a modified version of this protocol was used to purify the recombinant 
bacmid DNA. Cell pellets were resuspended in 300μl of Qiagen buffer P1, lysed by 
addition of 300μl of Qiagen buffer P2 at room temperature for five minutes and then 
incubated with 300μl of Qiagen buffer P3 on ice for ten minutes. The lysate was cleared 
at room temperature by centrifugation at 13,000rpm for 10 minutes. The cleared lysate 
700μl was added to 800μl ice cold isopropanol and incubated for 5 minutes on dry ice. 
Precipitated bacmid DNA was pelleted by centrifugation at 13,000rpm for 10 minutes at 
room temperature and the DNA pellet was washed with 70% (v/v) Ethanol. Eventually 
the DNA was resuspended in 50μl of sterile elution buffer (Qiagen) inside a laminar flow 
hood (sterile conditions). 
 
The baculovirus of the genes of interest were generated for protein production, 
and the Sf9 insect cell strain was used to amplify the baculovirus. Transfection mix was 
made by adding 10µl of FuGene HD transfection reagent into 100µl of serum-free media 
that contained 1-2µg of Bacmid DNA. The transfection mix was incubated at 27°C for 30 
minutes before being diluted with 1ml serum-free medium and incubated with 2×106 
healthy Sf9 cells in a 6-well plate. After transfection, another 2ml of serum-free medium 
was added back into the Sf9 cells for continuous incubation at 27°C for 4-5 days before 
the baculovirus was harvested. The 1st generation of virus needs to be amplified twice 
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before being used for infection. The amplification was performed in 25mm cell culture 
dishes with ~20×106 healthy Sf9 cells per dish. Each amplification mixture was made by 
mixing 500µl of 1st generation virus with 5ml of serum-free medium. Then the 
amplification mix was added into 25mm cell culture dishes before incubation at 27°C for 
2 hours. After 2 hours, another 15ml of serum-free medium was added into each dish for 
a continuous 3-day incubation at 27°C before the 2nd generation of baculovirus was 
harvested. The 3rd generation of baculovirus was prepared with the same procedure.  
 
 Hi-5 insect cells were infected or co-infected by the 3rd generation of baculovirus 
at a density of 10-20×106 cells/ml, and the infection was shaken at a speed of 120 
revolutions per min (rpm) and incubated at 27°C for 2 hours in a shaker incubator. After 
incubation, serum-free medium was added back to the infection and the cells were diluted 
to a density of 1-2×106 cells/ml. The diluted infections were shaken at a speed of 
155rpm/min and incubated at 27°C for one day and then at 20°C for anther two days 
before harvesting. 1ml of virus was used for each 100ml infection culture and the viruses 
used for co-infection were at a 1:1 ratio. 
 
 
Protein expression and purification 
 
Most of the protein complexes in this chapter were purified through GST and 
Strep affinity tags. For these purification, Hi-5 insect cell pellets were resuspended in a 
suspension buffer of 50mM Tris-HCl pH7.6, 0.3M NaCl, 5mM Dithiothreitol (DTT) 
supplemented with 10µg/ml Aprotinin, 5µg/ml Leupeptin, protease inhibitor 1 
tablet/50ml buffer (Sigma) and 2.5 mM phenylmethylsulphonyl fluoride (PMSF), and 
lysed by sonication on ice. Lysates were cleared at 15,000rpm for 20 minutes at 4°C 
twice, and the cleared lysates were incubated with glutathione-affinity resins (Qiagen) or 
strep-tactin sepharose (IBA). Lysates were gently shaken on a rotary shaker at 4°C for 1 
hour and then the beads were washed twice with two bead-volumes before loading onto 
the column.  Beads were washed in the column with at least 20 bead volumes before 
elution. Proteins were eluted out of affinity beads by 10mM GSH (Glutathione) or 
2.5mM dethiobiotin supplemented wash buffer (elution buffer), and the results were 
visualized through SDS-PAGE. For the protein complexes that required removal of the 
affinity tag, home made TEV protease, thrombin, or prescission was added to the elutions 
at a mass ratio of 1:50, 1:100, 1:100 (protease: eluted proteins), respectively. The eluted 
protein was concentrated to above 3mg/ml (measured by Bio-Rad Protein Assay) for the 
tag cleavage.  
 
For the native gel shift assay, protein complexes were purified by gel filtration 
chromatography using a Superose6 column (GE) in a buffer of 50mM Tris-HCl pH7.6, 
0.3M NaCl, 5mM DTT. The fractions of gel filtration were examined by SDS-PAGE to 
select the protein fractions of interest. The fractions of interest were pooled, concentrated 
with Amicon concenfugal filter units, aliquotted, flash-frozen in liquid nitrogen, and 
stored at -80°C until later use.   
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Native gel shift assays 
 
The electrophoresis for the native gel shift assays was performed with 1×TB 
buffer (90mM Tris-borate) pH 8.2. Native gels are a 4.5% poly-acrylamide gel with 2% 
glycerol, made of 40% acrylamide/bis solution (37.5:1, Biorad), 100% glycerol and 
5×TB buffer. Cdh1(full length or truncated)-Hsl130 was mixed with APC3ΔL-APC16 or APC8-
APC6-Cdc26-APC13 at a molar ratio of 10:1. APC3ΔL-APC16 or APC8-APC6-Cdc26-
APC13 were loaded with 21µM or 18µM for each mix, respectively. The mixes were 
diluted with the gel filtration buffer, 50mM Tris-Cl pH7.6, 0.3M NaCl, 5mM DTT, to a 
final volume of 8µl with 6.25% glycerol. For the control group, the same concentration of 
the protein complexes were used as those in the experimental group and were directly 
diluted by gel filtration buffer to 8µl with 6.25% glycerol. The diluted samples and mix 
were incubated on ice for 20 minutes before electrophoresis was performed in the cold 
room for 160mins (under 130V). The protein bands were visualized by commassie 
staining.  
 
 
WaterLOGSY 
 
The purified protein complexes for WaterLOGSY screening were buffer 
exchanged into 100mM phosphate-buffered saline (PBS) solution pH7.4 by NAP-5 
columns (GE). Protein complexes were then mixed with TAME and diluted with 100mM 
Na3PO4 pH7.0 buffer to a final volume of 500µl of 2mM protein complexes, 0.2mM 
TAME and 10% D2O. The samples were transferred to NMR tubes at room temperature 
and screened with a WaterLOGSY pulse sequence in Jet 600MHz (Bruker). All the 
preparation before the sample transfer was done on ice or in the cold room. For each 
sample, a reference spectrum and a 1D WaterLOGSY spectrum were recorded. Each 
spectrum was scanned for 30 rounds, and each round includes 8 dummy scan and 32 
scans.  
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CHAPTER 4. IMPLICATIONS AND FUTURE DIRECTIONS 
 
 
Insights from the Hybrid Structure of the C-terminal Portion of Human APC3 
 
The structural study of the human C-terminal APC3 leads to its structure 
determination. In the hybrid construct (the chimeric APC3), the C-terminal human APC3 
folded into α-helices with the predicted TPR boundaries, whereas two TPR regions 
folded into two α-helices instead of the canonical the α-helix-turn-α-helix (a TPR motif). 
However, the binding groove of APC3 (TPR8-10) independently adopted a canonical 
TPR folding without being affected by its neighbor mis-folded TPR7 and TPR11. The 
details demonstrated by the atomic model of the APC3 binding groove provided an 
accurate view to interpret current assays and help guide the design for later mutagenesis 
study to validate the structure.   
  
Although a mis-folded structure was generally considered to be uninformative, 
the atomic model of the chimeric APC3 turned out to be useful for structure analysis. The 
key information lies with a mis-folded helix α-11. The short alpha helix α-11 is folded 
from the predicted TPR11. Instead of packing parallel to TPR10, it was recruited to the 
binding groove. This phenomenon indicated the APC3 binding groove is functional even 
it is surrounded with five mis-folded or mis-orientated α-helices. The residues mediating 
the interactions between α-11 and the binding groove are different from those stabilizing 
the canonical TPR11 packing (Figure 2-15). Although it couldn’t be concluded that the 
formation of α-11 resulted from its recruitment to the binding groove, the fact of this mis-
folded helix indicates the binding groove is capable to mediate strong interactions and 
affect the canonical folding pattern. 
 
As to the binding groove TPRs 8-10, three dimensional structure alignments 
showed that the whole binding groove well matched other canonical TPR motifs and the 
α-11 overlapped with multiple binding partners of the matched hits (Figure 2-9). 
Furthermore, the fact that the α-11 was aligned onto the binding partners implied that α-
11 potentially played a role of a pseudo binding partner in the chimeric APC3 (Figure  
2-9). 
 
Based on the fact that α-11 locked the chimeric APC3 binding groove as a 
potential pseudo binding partner, the interactions between them partially represented the 
recruitment mechanism of the APC co-activators. Similarly, two residues: a Lysine and a 
Leucine, mimicked and represented the IR-tail (Isoleucine-Arginine) interactions, 
although the Lys and Leu were along a turn of α-11 instead of a peptide. The carboxyl 
group of the Lysine also formed a peptide bond. But these two residues (the Lysine an 
Leucine) were recruited to two featured binding pockets respectively and demonstrated 
the same types of the interactions as the IR-tails (Figure 2-10). The IR-tails have a free 
carboxyl group, which most likely contributed to the recruitment by interacting with a 
basic residue surrounding the negatively charged pocket. A highly conserved His551 of 
TPR7a (Figure 2-16a), a well conserved His589 and Arg587 of TPR8a (Figure 2-8a, 
Figure 2-10) are all close to the carboxyl group of IR-tail and could potentially mediate 
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another salt bridge. The IR-tail probably established stronger interactions with the 
binding groove than what were demonstrated by α-11 in the chimeric APC3. 
 
The chimeric APC3 structure provided clues to speculate the biological meaning 
of their interactions and a hypothetical model. Both the IR-tail residues and the APC3 
binding groove residues are conservative across species. This may indicate that it is 
critical to anchor the IR-tails (of the APC co-receptors) to the correct domain/region on 
APC3. The IR-tail interactions would potentially be much stronger comparing to the 
interactions of Cdh1 with APC8 and the APC platform (Figure 3-5, Figure 3-6, Figure 
3-7).  
 
The strong IR-tail interactions potentially keep the co-activators (Cdh1 and 
Cdc20) and APC10 bound to the APC during APC active stages. Considering that Cdh1 
repositioned itself on the APC during substrate recruitment and ubiquitination (31, 32), 
the strong IR-tail interactions with APC3 would keep Cdh1 associating with the APC 
during its orientation change. As for APC10, a constituent subunit of the APC, it has a 
role for optimal Cdh1/Cdc20-dependent substrate recognition and substrate ubiquitination 
processivity (38). However, it is not well understood how APC10 contributes to the 
formation of poly-ubiquitin chains and whether it also has a movement on the APC. But 
the IR-tail is the only domain of APC10 that connects to APC3, which potentially 
requires the interactions strong enough to support the APC10 function.  
 
The mis-folded TPRs inside the chimeric APC3 also provided clues for 
speculation of TPR protein folding mechanism to understand the biological meaning of 
their superhelix tertiary structure. The superhelix ensures the binding groove more 
accessible to unstructured the peptides (etc. IR tails) rather than numerous, random α-
helices surrounding APC3 (Figure 2-17). The correctly folded TPRs also served as an 
accurate model for APCEM docking.  
 
 
Strength and Weakness of Hybrid TPR Proteins/Technology 
 
 
Brief introduction to the hybrid proteins strategy 
 
The first successful hybrid protein was reported on the human Toll-like receptor 
4. Toll-like receptors are a class of proteins that play a key role in the innate immune 
system, and they belong to the Leucine rich repeats (LRR) protein family. LRR is a 
protein structural motif composed of repeating 20–30 amino acids that are unusually rich 
in the hydrophobic amino acid Leucine. Commonly a LRR motif forms an α helix-turn-β 
strand, and these repeats pack parallel to each other and form a horseshoe-like solenoid. 
 
The basic concept of hybrid proteins is to replace a crystallization hindrance 
region of one protein with a homologous but crystallizable domain from its homologs 
(Figure 2-1). The homologous domains were supposed to benefit crystallization without 
changing or affecting the protein folding. The structure of human Toll-like receptor 4 was 
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determined through a series of hybrids (65), because the receptor itself (full-length or 
truncated) could not generate crystals. In order to help crystallization, the modules of 
hagfish variable lymphocyte receptors (VLR) were fused to substitute the insoluble part 
of the human toll-like receptor 4. These hybrid receptors crystallized and led to the 
structure determination. 
 
In pursuit of human APC3 structure, both the full-length or truncated APC3 could 
not crystalize. The N-terminal E. cuniculi APC3 atomic structure was published around 
that time, which includes the N-terminal TPRs 1-6 (PDB code: 3KAE). TPRs 1-4 
mediate the E. cuniculi APC3 dimerization, followed by a 20-residue insert and TPR5-6 
(Figure 2-1). However, the N-terminal dimerization domain of human APC3 expressed 
poorly in vitro and the following disordered insert has 270 residues (Figure 2-1). These 
two regions were both crystallization hindrance. Since the corresponding region in E. 
cuniculi APC3 was crystallizable, it was used to substitute the insoluble domains of 
human APC3.  
 
 
Comparisons of LRR and TPR proteins 
 
To this day, the hybrid technology has a couple successes in crystallizing LRR 
(Leucine rich repeats) proteins. Another example is a hybrid InlB variant YopM-InlB. 
InternalinB is an agonist of L. monocytogenes to the human receptor tyrosine kinase MET 
(91). Whereas YopM is a surface effector of Y.pestis that binds caspase-1 to inhibit its 
activity and sequesters it to block formation of a mature inflammasome (92). YopM and 
InlB are two functionally non-related LRR proteins. The cap domain of YopM replaced 
the cap of InlB protein, which originally folded into two α-helices but became shorter in 
the hybrid protein. The residues at the hybrid interface also mildly shifted from original 
positions, but the interface didn’t cause substantially global changes of the InlB structure 
(66). The hyrbrid YopM-InlB addressed the biological function of the N-terminal cap of 
internalins, which could not be studied with simple domain deletion constructs due to its 
indispensability to correct protein folding.  
 
Although both LRR and TPR proteins are featured with repeat structure motifs, 
they are quite different. The difference of LRR proteins and TPR proteins are listed in the 
Table 4-1. Repeat proteins are involved in many important protein–protein interactions in 
most organisms, and LRR proteins have more rigid structural motifs to make their tertiary 
structures more repeatable among each other. Most LRR proteins form solenoid 
structures of a horseshoe with the motifs of an α-helix/β-strand. Structures of four 
functionally non-related LRR proteins are well superimposed onto each other and the 
overlapped horseshoes have elongated and curved shapes with similar radii, although the 
length of each protein vary (Figure 4-1, left).  
 
The conserved structural packing of the LRR family is probably contributed from 
their consensus sequence of the structural motifs, which is enriched with Leucine and a 
few other hydrophobic residues. For example, the consensus sequence in the LRR motif 
of human TLR4 (Toll-like receptor 4) consists of Leucine and Phenylalanine. These two   
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Table 4-1. Comparison of LRR (Leucine rich repeat) and TPR 
(Tetratricopeptide repeat) proteins. 
 
Comparisons LRR proteins 
(Leucine rich repeats) 
TPR proteins 
(Tetratricopeptide repeats) 
Motifs An α-helix-turn-β-strand Two antiparallel helices 
Packing Stacking to form solenoid 
structures of a horseshoe 
Paralleling to solenoid 
structures of a super helix 
Folding Independently folding, long 
or short hybrids folds 
correctly) 
Less conserved TPRs, tend to 
depend on the neighbor TPRs 
or the protein tertiary 
structures  
Consensus 
sequence 
More conserved consensus 
sequence of structural motifs 
(from a large number of 
functionally unrelated 
proteins) 
Consensus sequence of 
structural motifs are not 
identified 
Repeat unit 310-helices in a strict length 
(of one motif) 
Repeat units of an average 34 
residues (one TPR motif) 
Function Protein scaffold, mediate 
protein-protein interactions 
Protein scaffold, mediate 
protein-protein interactions 
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Figure 4-1. Leucine rich repeat proteins have repeatable structural framework 
with rigid structural motifs. 
 
Left: A structural superimposition of five different LRR proteins, with the name and PDB 
code of each protein labeled in the same color as the backbone in the structures. 
Right: Illustration of the interactions that stabilize the packing of structure motifs in the 
human toll-like receptor 4. The warm pink sticks indicate Leucine and purple sticks 
indicate Phenylalanine.  
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residues mainly mediate the inter-motif and intra-motif packing (Figure 4-1, right) and 
the simple interaction pattern is potentially responsible for rigid repeat units, which 
results in human TLR4 has a repeatable scaffold (tertiary structure) as other LRR proteins 
 
Comparing to the LRR proteins interaction pattern, TPR proteins demonstrate 
complicate interaction “networks”. TPR protein is featured by TPR motifs packed 
parallel to each other. Instead of stacking to form an elongated horseshoe, most TPR 
proteins fold into a superhelix with their TPRs. The “networks” are possible because one 
α-helix of a TPR motif is usually surrounded by four other α-helices, rather than being 
simply flanked by an upstream and a downstream α-helices. This local architecture 
allows one helix close to four α-helices and the center α-helix could establish interactions 
with all four of them. Both human APC3 and APC6 demonstrate this structure (Figure  
4-2). 
 
Sharing the complexity inside the TPR interaction networks, TPR protein residues 
that mediate the interactions show high diversity comparing to the LRR proteins. The 
rigid LRR motifs have consensus sequence, which make the LRR protein folding more 
predictable. Contrastingly, no consensus sequence could be identified for TPR motifs. 
Instead, TPR motifs use various hydrophobic residues to organize/support/build up the 
interaction networks. For instance, human APC3 TPR9a contacts TPR 8a and 10a besides 
establishing packing interactions with two neighbor α-helices TPR 8b and 9b (Figure 
4-2, left). A Tyr and a Leu of human APC3 TPR9a interact with a Glu and an Asn of the 
TPR8a, respectively, and an Ala from TPR9a interacts with a His of TPR10a. In another 
example of human APC6, APC6 TPR8b contacts an Ile and a His of TPR7b with a Pro 
and a Tyr, whereas two Leu on the other side of the TPR8b contact with two Val of 
TPR9b (Figure 4-2, right). The residues to mediate intra-TPR interactions could include 
all hydrophobic residues instead of a few. Furthermore, all these residues show no 
repeatable or predictable positions in the protein sequence. There are more complexities 
in TPR protein folding with respect to interaction networks and protein sequence.  
 
 
The strength and weakness of the TPR hybrid technology 
 
There are advantages of hybrid protein technology. Generally, the successful 
hybrid proteins have better behaviors and showed the higher potential for crystallization, 
which offer the opportunities for structure studies and determination. Through the 
chimeric APC3 structures, it seems like the highly conserved TPR domains have higher 
chance to follow canonical folding in the hybrid proteins. The structures of these 
conserved domains provide the guidance for further studies and experimental designs. On 
the other hand, it is interesting to know that TPR proteins have the potential to adopt 
alternative folding to be soluble. Biologically, this could lower down the cell stress when 
the gene mutations happen or protein-folding machineries make mistakes. Furthermore, 
the domain swapping strategy also creates an approach to test the function of an essential 
domain which could neither be separated from the original protein nor be functional on 
its own (66).   
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Figure 4-2. TPR proteins have interaction networks involved in TPR motif 
packing. 
 
Illustration of TPR protein interaction networks from human APC3 (left) and APC6 
(right), with the residues mediating the interactions labeled out with lines and sticks. The 
lines indicate that residues mediate the center α-helix packing to its neighbor α-helices, 
and those residues are shown in the bottom sequence in black color. Similarly, sticks 
indicate the residues involved in the center α-helix contacting distant α-helices and they 
are shown at the bottom in green (human APC3, left) and orange (human APC6, right). 
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However, the risks of TPR hybrids are higher than the LRR hybrids. The interface 
of a hybrid protein potentially affects the downstream protein peptide folding since both 
LRR and TPR proteins pack based on the interaction among their consecutive structural 
units. Because TPR proteins are featured with more complicate interactions (cross-TPRs) 
mediated by a variety of residues, they are more sensitive to the domain swap. The hybrid 
YopM-InlB has the motif immediately following the YopM cap affected, while the rest of 
the hybrid protein kept the same scaffold (66). In the chimeric APC3, TPR7 failed to be 
stabilized by TPR6 and leads to the orientation of the whole protein changed.  
 
Combining the consensus sequence and available atomic structures, the 
hydrophobic cores of LRR proteins are more stable and predictable than TPR proteins. 
Synthetic libraries of designed LRR proteins have been designed and used for generating 
artificial binders that replace antibodies (93). So far there is no such libraries for TPR 
proteins. However, the available atomic models from TPR proteins are increasing, which 
help to improvement from the protein structure prediction and analysis. As for TPR 
protein hybrids, the combination of multiple approaches will be required to design 
successful fusion structures, i.e. the homologous atomic models, structure prediction, 
EM-derived models. Meanwhile, the following strict and careful analyses are also 
essential to examine the authenticities of atomic structures. 
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APPENDIX. SUPPLEMENTARY DATA FOR STRUCTURAL STUDIES OF THE 
TPR SUBUNITS OF THE HUMAN APC 
 
 
 
 
 
Figure A-1. Intact masspectra of the SeMet incorporated and native chimeric 
APC3. 
 
The molecular weight of the SeMet incorporated and native chimeric APC3 are 
42198.93Da and 41684.77 Da, detected by the Intact masspectrometry. A 
SelenoMethione has a molecular weight of 196.11Da and a Methionine weight 149.21Da. 
The incorporated Selenium sites are about 10 for each purified protein, which is 
calculated from (42198.93-41684.77)/(196.11-149.21)=10.35.  
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Figure A-2. Different crystal forms of the chimeric APC3. 
 
Different crystal forms of the SeMet labeled (top), MBP-(AAA)- fused (middle), and 
Lysine methylated chimeric APC3, with the schematics of the corresponding constructs 
on the left. The crystallization conditions are:  
Top: 0.1M HEPEs pH 7.0, 0.2M AmSO4, and 48-51% MPD, at room temperature.   
Middle:  0.1M BTP pH7.5, 20% PEG3350, and 0.2M NaI, at room temperature. 
Bottom: Lysine methylated  0.1M CAPS pH10.5 and 40% MPD, at 4°C. 
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Figure A-3. The structural comparison of the N-terminal APC7 and APC3.  
 
The 3D superimposition of the N-terminal human APC7 TPR1-4 (PDB code: 3FFL) onto 
the EM-derived human APC3 (TPR1-4). The α-helices are displayed in the shapes of 
cyclinders with the TPR numbers labeled. 
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Table A-1. A crystallization summary of the APC TPR subunits. 
 
Complex Details Crystalization 
screening description 
Hits Crystal optimization 
summary 
Results 
APC3ΔL-
APC1674 
Human APC3Δ(183-452), 
with APC16 residues 74-
110, co-purified, 
stoichiometry 2:1 
Robotic screen around 
2,000 conditions at 4°C 
& RT 
Yes Robotic screening of 250 
conditions and manual 
screening/optimization in 500 
conditions 
Diffraction 
around 5Å 
APC3ΔL-
APC1674-
Cdh1fl-
Hsl130 
Human APC3Δ(183-452), 
APC16 residues 74-110, 
Cdh1 full-length and yeast 
Hsl1 includes KEN and D 
box, co-purified, 
stoichiometry 2:1:2:2 
Robotic screen around 
2,000 conditions at 4°C 
& RT 
Yes Robotic screening of 96 
additives and manual 
screening/optimization in 290 
conditions 
Diffraction 
around 7Å 
APC8fl-
APC6s-
Cdc26s 
Human APC8 full-length 
with APC6residues 212-539, 
Cdc26 residues 1-29, co-
purified, stoichiometry 1:1:1 
Robotic screen around 
2,600 conditions at 4°C 
& RT for each complex 
4°C & RT 
Yes Robotically and manually 
screen 360 conditions 
Diffraction 
around 3Å, 
but APC8 
doesn't pack 
in the crystals 
APC8fl-
APC6l-
Cdc26s 
Human APC8 full-length 
with APC6residues 1-539, 
Cdc26 residues 1-29, co-
purified, stoichiometry 1:1:1 
Robotic screen around 
2,800 conditions at 4°C 
& RT for each complex 
4°C & RT 
No — — 
APC8fl-
APC6fl-
Cdc26fl 
Human and zebrafish full-
length proteins of APC8, 
APC6, Cdc26, co-purified, 
stoichiometry 1:1:1 
Robotic screen around 
2,400 conditions at 4°C 
& RT for each complex 
No — — 
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Figure A-4. Crystallization of the human APC3∆L-APC1674. 
 
A brief summary of the purification and the crystallization of the human APC3∆L-
APC1674. Each component of the protein complex is schematically illustrated (top panel) 
The middle panel is a gel filtration profile from the purification of the protein complex 
(left), with the complex fractions examined by SDS-PAGE (right). The pooled fractions 
are labeled out with a purple line at the bottom of the gel. The purified APC3∆L-
APC1674 generated hits in the condition of 0.1M BTP pH 7.5, 10% PEG3350 at room 
temperature (bottom left) and the crystals diffracted to ~6Å. 
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Figure A-5. The crystallization summary of APC3∆L-APC1674-Cdh1-Hsl30. 
 
A brief summary of the purification and the crystallization of the human APC3∆L-
APC1674-Cdh1-Hsl30. Each component in the protein complex is schematically illustrated 
(top panel). The middle panel is a gel filtration profile from the purification of the protein 
complex (left), with the complex fractions examined by SDS-PAGE (right). The pooled 
fractions are labeled out with a purple line at the bottom of the gel. The purified 
APC3∆L-APC1674-Cdh1-Hsl30 generated hits at 4˚C in the conditions of 0.1M BTP pH 
7.0, 0.4M Mg-Formate (bottom left) and 0.1M MES pH 6.5, 0.5M AmSO4 (bottom 
middle). The crystals diffracted to ~7Å. 
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Figure A-6. Human Cdh1 N-terminal secondary structure prediction from 
Psipred (68). 
 
The human Cdh1 sequence refers to 496 a.a (Uniprot code: Q9UM11). The pink 
cylinders indicate the α-helices and yellow arrows indicate the β-sheets. The residue 
numbers are labeled under the protein sequence.  
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